var title_f33_58_34720="Clotrimazole: Pediatric drug information";
var content_f33_58_34720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clotrimazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/6/15460?source=see_link\">",
"       Clotrimazole (oral): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/28/13763?source=see_link\">",
"       Clotrimazole (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13173 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.22.229.50-9649136F8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34720=[""].join("\n");
var outline_f33_58_34720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/6/15460?source=related_link\">",
"      Clotrimazole (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/28/13763?source=related_link\">",
"      Clotrimazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34721="Seborrheic dermatitis face";
var content_f33_58_34721=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical involvement of the cheeks and nasolabial folds is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34721=[""].join("\n");
var outline_f33_58_34721=null;
var title_f33_58_34722="Patient information: High blood pressure in adults (The Basics)";
var content_f33_58_34722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15329\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/16/6411\">",
"         Definition of normal and high blood pressure",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/39/22130\">",
"         Patient information: Abdominal aortic aneurysm (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/14/12512\">",
"         Patient information: Carotid artery disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/57/27539\">",
"         Patient information: High blood pressure emergencies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/19/41266\">",
"         Patient information: Low-sodium diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/40/23171\">",
"         Patient information: Medicines for high blood pressure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/54/33635\">",
"         Patient information: High blood pressure in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/28/38337\">",
"         Patient information: High blood pressure in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/32/37380\">",
"         Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/58/931\">",
"         Patient information: High blood pressure treatment in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?9/8/9347\">",
"         Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: High blood pressure in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/high-blood-pressure-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24362989\">",
"      <span class=\"h1\">",
"       What is high blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;High blood pressure is a condition that puts you at risk for heart attack, stroke, and kidney disease. It does not usually cause symptoms. But it can be serious.",
"     </p>",
"     <p>",
"      When your doctor or nurse tells you your blood pressure, he or she will say two numbers. For instance, your doctor or nurse might say that your blood pressure is &ldquo;140 over 90.&rdquo; The top number is the pressure inside your arteries when your heart is contracting. The bottom number is the pressure inside your arteries when your heart is relaxed.",
"     </p>",
"     <p>",
"      This table shows how doctors and nurses define high and normal blood pressure (",
"      <a class=\"graphic graphic_table graphicRef59480 \" href=\"mobipreview.htm?6/16/6411\">",
"       table 1",
"      </a>",
"      ). &ldquo;Prehypertension&rdquo; is a term doctors or nurses use as a warning. People with prehypertension do not yet have high blood pressure. But their blood pressure is not as low as it should be for good health.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24362996\">",
"      <span class=\"h1\">",
"       How can I lower my blood pressure?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor or nurse has prescribed blood pressure medicine, the most important thing you can do is to take it. If it causes side effects, do not just stop taking it. Instead, talk to your doctor or nurse about the problems it causes. He or she may be able to lower your dose or switch you to another medicine. If cost is a problem, mention that too. He or she may be able to put you on a less expensive medicine. Taking your blood pressure medicine can keep you from having a heart attack or stroke, and it can save your life!",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24363003\">",
"      <span class=\"h1\">",
"       Can I do anything on my own?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You have a lot of control over your blood pressure. To lower it:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lose weight (if you are overweight)",
"       </li>",
"       <li>",
"        Choose a diet low in fat and rich in fruits, vegetables, and low-fat dairy products",
"       </li>",
"       <li>",
"        Reduce the amount of salt you eat",
"       </li>",
"       <li>",
"        Do something active for at least 30 minutes a day on most days of the week",
"       </li>",
"       <li>",
"        Cut down on alcohol (if you drink more than 2 alcoholic drinks per day)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It&rsquo;s also a good idea to get a home blood pressure meter. People who check their own blood pressure at home do better at keeping it low and can sometimes even reduce the amount of medicine they take. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24363052\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=see_link\">",
"       Patient information: Medicines for high blood pressure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/14/12512?source=see_link\">",
"       Patient information: Carotid artery disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/39/22130?source=see_link\">",
"       Patient information: Abdominal aortic aneurysm (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=see_link\">",
"       Patient information: Low-sodium diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=see_link\">",
"       Patient information: High blood pressure emergencies (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=see_link\">",
"       Patient information: High blood pressure in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=see_link\">",
"       Patient information: High blood pressure in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=see_link\">",
"       Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=see_link\">",
"       Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=see_link\">",
"       Patient information: High blood pressure treatment in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/58/34722?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15329 Version 7.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-EA4EE1DDAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34722=[""].join("\n");
var outline_f33_58_34722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24362989\">",
"      What is high blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24362996\">",
"      How can I lower my blood pressure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24363003\">",
"      Can I do anything on my own?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24363052\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/16/6411\">",
"      Definition of normal and high blood pressure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/39/22130?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/57/27539?source=related_link\">",
"      Patient information: High blood pressure emergencies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/54/33635?source=related_link\">",
"      Patient information: High blood pressure in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/28/38337?source=related_link\">",
"      Patient information: High blood pressure in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/32/37380?source=related_link\">",
"      Patient information: High blood pressure treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/58/931?source=related_link\">",
"      Patient information: High blood pressure treatment in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/19/41266?source=related_link\">",
"      Patient information: Low-sodium diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/40/23171?source=related_link\">",
"      Patient information: Medicines for high blood pressure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34723="Neomycin, polymyxin B, and gramicidin: Drug information";
var content_f33_58_34723=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin, polymyxin B, and gramicidin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/61/27604?source=see_link\">",
"    see \"Neomycin, polymyxin B, and gramicidin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg; Ophthalmic Solution",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin&reg;;",
"     </li>",
"     <li>",
"      Optimyxin Plus&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Instill 1-2 drops 4-6 times/day or more frequently as required for severe infections",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic [drops]: Neomycin 1.75 mg, polymyxin B 10,000 units, and gramicidin 0.025 mg per 1 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neosporin&reg; Ophthalmic Solution: Neomycin 1.75 mg, polymyxin B 10,000 units, and gramicidin 0.025 mg per 1 mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial ocular infection",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Transient irritation, burning, stinging, itching, inflammation, angioneurotic edema, urticaria, vesicular and maculopapular dermatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, gramicidin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin sensitization: Symptoms of neomycin sensitization include itching, reddening, edema, and failure to heal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects (prolonged use): Glaucoma, defects in visual acuity, posterior subcapsular cataract formation, and secondary ocular infections may result from prolonged use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F177325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination; therefore, Neomycin, Polymyxin B, and Gramicidin is classified as pregnancy category C. See individual monographs for Neomycin and Polymyxin B.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7413790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7413789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if neomycin, polymyxin B, or gramicidin is excreted into breast milk. The manufacturer recommends that caution be exercised when administering Neomycin, Polymyxin B, and Gramicidin to nursing women. See individual monographs for Neomycin and Polymyxin B.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Neosporin (CA);",
"     </li>",
"     <li>",
"      Optimyxin Plus (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits; binds to phospholipids, alters permeability, and damages the bacterial cytoplasmic membrane permitting leakage of intracellular constituents",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abramowicz M, &ldquo;Antimicrobial Prophylaxis in Surgery,&rdquo;",
"      <i>",
"       Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy",
"      </i>",
"      , 16th ed, New York, NY: Medical Letter, 2002.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9689 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34723=[""].join("\n");
var outline_f33_58_34723=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177336\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177337\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177347\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177340\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177344\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177341\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177329\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177317\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177330\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177345\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177321\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299754\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177325\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177326\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413786\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413790\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413789\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177334\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177320\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9689\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9689|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/61/27604?source=related_link\">",
"      Neomycin, polymyxin B, and gramicidin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34724="Oprelvekin: Drug information";
var content_f33_58_34724=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oprelvekin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/19/26933?source=see_link\">",
"    see \"Oprelvekin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/54/37732?source=see_link\">",
"    see \"Oprelvekin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neumega&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F203877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Biological Response Modulator;",
"     </li>",
"     <li>",
"      Human Growth Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of thrombocytopenia:",
"     </b>",
"     SubQ: 50 mcg/kg once daily for ~10-21 days (until postnadir platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer first dose ~6-24 hours after the end of chemotherapy. Discontinue at least 48 hours before beginning the next cycle of chemotherapy.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9604650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: 25 mcg/kg once daily for ~10-21 days (until postnadir platelet count &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neumega&reg;: 5 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Subcutaneously in the abdomen, thigh, hip, or upper arm.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of severe thrombocytopenia; reduce the need for platelet transfusions following myelosuppressive chemotherapy for nonmyeloid malignancy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Oprelvekin may be confused with aldesleukin, Proleukin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Neumega&reg; may be confused with Neulasta&reg;, Neupogen&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F203875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (children 84%; adults 20%), edema (59%), cardiomegaly (children 21%), vasodilation (19%), atrial arrhythmia (12% to 15%), palpitation (14%), syncope (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Neutropenic fever (48%), headache (41%), dizziness (38%), fever (36%), insomnia (33%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (77%), diarrhea (43%), mucositis (43%), oral moniliasis (14%), weight gain (due to fluid retention)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (dilutional; onset: 3-5 days; duration: &le;1 week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (severe 14%), periostitis (children 11%), arthralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctival injection/redness/swelling (children 57%; adults 19%), papilledema (children 16%; adults 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (48%), rhinitis (42%), cough (29%), pharyngitis (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Respiratory: Pleural effusion (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, amblyopia, anaphylaxis/anaphylactoid reactions, blindness, blurred vision, capillary leak syndrome, cardiac arrest, chest pain, dehydration, dysarthria, exfoliative dermatitis, eye hemorrhage, facial edema, fibrinogen increased, fluid overload, HF, hypoalbuminemia, hypocalcemia, hypokalemia, hypotension, injection site reactions (dermatitis, pain, discoloration), loss of consciousness, mental status changes, optic neuropathy, paresthesia, pericardial effusion, peripheral edema, pneumonia, pulmonary edema, renal failure, shock, skin discoloration, stroke, urticaria, ventricular arrhythmia, visual acuity changes, visual field defect, von Willebrand factor concentration increased, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oprelvekin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia (dilutional): Dilutional anemia (reversible) may occur due to increased plasma volume; generally appears within 3-5 days of initiation of therapy and resolves over ~1 week following discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular effects: Atrial arrhythmias, pulmonary edema, and cardiac arrest have been reported; use in patients with a history of atrial arrhythmia only if the potential benefit exceeds possible risks. Patients experiencing arrhythmia may be at risk for stroke. Ventricular arrhythmia has also been reported, occurring within 2-7 days of treatment initiation; use with caution in patients with conduction defects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: May cause serious fluid retention (reversible) which may result in peripheral edema, capillary leak syndrome, arrhythmias, or exacerbation of pleural effusion. Use cautiously in patients with conditions where expansion of plasma volume should be avoided (eg, left ventricular dysfunction, HF, hypertension). Monitor fluid balance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactoid reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Allergic or hypersensitivity reactions, including anaphylaxis have been reported. Permanently discontinue in any patient developing an allergic or hypersensitivity reaction.",
"     </b>",
"     May occur with the first or with subsequent doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Papilledema: Dose limiting papilledema, more frequently associated with use in children, has occurred (usually following repeated cycles); use with caution in patients with pre-existing papilledema or with tumors involving the central nervous system; may worsen pre-existing papilledema. Patients experiencing oprelvekin-related papilledema may be at risk for visual acuity changes, including blurred vision or blindness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ascites/pericardial effusion: Use with caution in patients with pre-existing pericardial effusions or ascites; may cause exacerbation of effusion. Consider drainage if indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in severe renal impairment. Monitor fluid balance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic disease: Use with caution in patients with a history of stroke, transient ischemic attack, or thromboembolic problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemotherapy regimens: Efficacy has not been established with chemotherapy regimens &gt;5 days duration or with regimens associated with delayed myelosuppression (eg, nitrosoureas, mitomycin). Not indicated following myeloablative chemotherapy; increased toxicities were reported when used following myeloablative therapy. A higher incidence of adverse events has been reported when used following bone marrow transplantation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diuretics: Closely monitor fluid and electrolytes in patient on chronic diuretic therapy; severe hypokalemia contributing to sudden death have been reported in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Although used in children in clinical trials, safety and efficacy have not been established in children. The incidence of certain adverse events may be higher in children. Use in children, especially &lt;12 years of age, should be as part of a clinical trial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Begin 6-24 hours following completion of chemotherapy; use has not been adequately studied immediately before or during chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic administration: Safety and efficacy have not been established with chronic administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3277319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated adverse fetal effects. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefits outweigh the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3277361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Neumega Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $336.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F203842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor electrolytes and fluid balance during therapy; obtain a CBC at regular intervals during therapy; monitor platelet counts until adequate recovery has occurred; renal function (at baseline)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Jijufen (CL);",
"     </li>",
"     <li>",
"      Neumega (BR, CO, IL, MX);",
"     </li>",
"     <li>",
"      Yi Xing (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oprelvekin is a thrombopoietic growth factor which stimulates multiple stages of megakaryocytopoiesis and thrombopoiesis, resulting in proliferation of megakaryocyte progenitors and megakaryocyte maturation, thereby increasing platelet production.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: 5-9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Du X and Williams DA, &ldquo;Interleukin-11: Review of Molecular, Cell Biology, and Clinical Use,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1997, 89(11):3897-908.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gordon MS, &ldquo;Thrombopoietic Activity of Recombinant Human Interleukin 11 in Cancer Patients Receiving Chemotherapy,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1996, 38 (Suppl):96-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tepler I, Elias L, Smith JW 2d, et al, &ldquo;A Randomized Placebo-Controlled Trial of Recombinant Human Interleukin-11 in Cancer Patients With Severe Thrombocytopenia Due to Chemotherapy,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1996, 87(9):3607-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34724/abstract-text/8611684/pubmed\" id=\"8611684\" target=\"_blank\">",
"        8611684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teramura M, Kobayashi S, Yoshinaga K, et al, &ldquo;Effect of Interleukin 11 on Normal and Pathological Thrombopoiesis,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 1996, 38 (Suppl):99-102.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9542 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34724=[""].join("\n");
var outline_f33_58_34724=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709182\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203860\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203877\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203862\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203863\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9604650\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203844\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203828\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203847\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203845\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203884\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203875\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203850\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203832\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299793\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203837\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203840\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3277319\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203867\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3277361\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323558\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203842\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539907\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203831\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203849\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9542\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9542|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/19/26933?source=related_link\">",
"      Oprelvekin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/54/37732?source=related_link\">",
"      Oprelvekin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34725="Amyloid high power HandE";
var content_f33_58_34725=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power magnification of blood vessels (a) and lamina propria (b) using hematoxylin and eosin stain from a patient with gastrointestinal amyloidosis. There is prominent infiltration by eosinophilic amyloid deposits (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Camilleri, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34725=[""].join("\n");
var outline_f33_58_34725=null;
var title_f33_58_34726="Atenolol: Pediatric drug information";
var content_f33_58_34726=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atenolol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"    see \"Atenolol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/27/2486?source=see_link\">",
"    see \"Atenolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6172803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tenormin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atenol&reg;;",
"     </li>",
"     <li>",
"      Ava-Atenolol;",
"     </li>",
"     <li>",
"      CO Atenolol;",
"     </li>",
"     <li>",
"      Dom-Atenolol;",
"     </li>",
"     <li>",
"      JAMP-Atenolol;",
"     </li>",
"     <li>",
"      Mint-Atenolol;",
"     </li>",
"     <li>",
"      Mylan-Atenolol;",
"     </li>",
"     <li>",
"      Nu-Atenol;",
"     </li>",
"     <li>",
"      PMS-Atenolol;",
"     </li>",
"     <li>",
"      RAN&trade;-Atenolol;",
"     </li>",
"     <li>",
"      ratio-Atenolol;",
"     </li>",
"     <li>",
"      Riva-Atenolol;",
"     </li>",
"     <li>",
"      Sandoz-Atenolol;",
"     </li>",
"     <li>",
"      Septa-Atenolol;",
"     </li>",
"     <li>",
"      Tenormin&reg;;",
"     </li>",
"     <li>",
"      Teva-Atenolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1051225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1051219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"      see \"Atenolol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Hypertension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 0.5-1 mg/kg/day given once daily or divided in 2 doses per day; titrate dose to effect; usual range: 0.5-1.5 mg/kg/day; maximum dose: 2 mg/kg/day; do not exceed adult maximum dose of 100 mg/day (National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 25-50 mg once daily; titrate dose to effect; usual dose: 50-100 mg once daily; usual dosage range (JNC 7): 25-100 mg once daily; maximum dose: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      See table for oral dosing interval in renal impairment.",
"     </b>",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"205\">",
"     </col>",
"     <col align=\"center\" width=\"155\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Creatinine Clearance",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Maximum Oral Dose",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Frequency of Administration",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         15-35 mL/min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg or 1 mg/kg/dose",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Daily",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;15 mL/min",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         50 mg or 1 mg/kg/dose",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Every other day",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenormin&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenormin&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenormin&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1051229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1051228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents (FDA approved in adults); management of angina pectoris (FDA approved in adults); post-MI patients (to reduce cardiovascular mortality) (FDA approved in adults); acute alcohol withdrawal; supraventricular and ventricular arrhythmias; migraine headache prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F137486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Atenolol may be confused with albuterol, Altenol&reg;, timolol, Tylenol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tenormin&reg; may be confused with Imuran&reg;, Norpramin&reg;, thiamine, Trovan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, heart failure, hypotension, persistent bradycardia, Raynaud's phenomenon, second- or third-degree AV block",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, dizziness, fatigue, headache, insomnia, lethargy, mental impairment, nightmares",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, dyspnea (especially with large doses), hallucinations, impotence, liver enzymes increased, lupus syndrome, Peyronie's disease, positive ANA, psoriasiform rash, psychosis, thrombocytopenia, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1051234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atenolol or any component; pulmonary edema, cardiogenic shock, bradycardia, heart block, or uncompensated CHF",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1051218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and modify dosage in patients with renal impairment; use with caution in patients with CHF, bronchospastic disease, diabetes mellitus, and hyperthyroidism. Use with caution in nursing women; clinically significant bradycardia may occur in breast-fed infants; infants with renal dysfunction and premature infants may be at higher risk for adverse effects; breast-fed infants and neonates born to mothers receiving atenolol may be at increased risk for hypoglycemia. Patients who have a history of anaphylactic hypersensitivity reactions to various substances may be more reactive while receiving beta-blockers; these patients may not be responsive to the normal doses of epinephrine used to treat hypersensitivity reactions.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1051217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exacerbation of angina, arrhythmias, and, in some cases, MI may occur following abrupt discontinuation of beta-blockers",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid abrupt discontinuation, wean slowly, and monitor for signs and symptoms of ischemia. Atenolol should not be administered to patients with untreated pheochromocytoma. Atenolol may mask clinical signs of hyperthyroidism (exacerbation of symptoms of hyperthyroidism, including thyroid storm, may occur following abrupt discontinuation). Atenolol decreases the ability of the heart to respond to reflex adrenergic stimuli and may increase the risk of general anesthesia and surgical procedures; use caution with anesthetic agents that decrease myocardial function. Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: May decrease the bioavailability of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus; therefore, the manufacturer classifies atenolol as pregnancy category D. Atenolol crosses the placenta and is found in cord blood. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. The maternal pharmacokinetic parameters of atenolol during the second and third trimesters are within the ranges reported in nonpregnant patients. Although atenolol has shown efficacy in the treatment of hypertension in pregnancy, it is not the drug of choice due to potential IUGR in the infant.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1051224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, ECG, fluid intake and output, daily weight, respiratory rate",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1051216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks response to beta-adrenergic stimulation; selectively blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors except at high doses; does not possess membrane stabilizing or intrinsic sympathomimetic (partial agonist) activities",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1051232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Beta-blocking effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Oral: &le;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Oral: &ge;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antihypertensive effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: Oral: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1051233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Incomplete from the GI tract; &sim;50% absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not cross the blood-brain barrier; low lipophilicity; distributes into breast milk at a concentration 1.5-6.8 times the maternal plasma concentration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Low (6% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, beta:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: Mean: 16 hours, up to 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-16 years of age: Mean: 4.6 hours; range: 3.5-7 hours; children &gt;10 years of age may have longer half-life (&gt;5 hours) compared to children 5-10 years of age (&lt;5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 6-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prolonged half-life with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 40% as unchanged drug in urine, 50% in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1051223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/27/2486?source=see_link\">",
"      see \"Atenolol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abrupt withdrawal of the drug should be avoided",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1051235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In diabetic patients, atenolol may potentiate hypoglycemia and mask signs and symptoms of hypoglycemia; limited data suggests that atenolol may have a shorter half-life and faster clearance in patients with Marfan syndrome. Higher doses (2 mg/kg/day divided every 12 hours) have been used in patients with Marfan syndrome (6-22 years of age) to decrease aortic root growth rate and prevent aortic dissection or rupture; further studies are needed.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F137404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 2 mg/mL oral suspension may be made with tablets. Crush four 50 mg tablets in a mortar and reduce to a fine powder. Add a small amount of glycerin and mix to a uniform paste. Mix while adding Ora-Sweet&reg; SF vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;.  Stable for 90 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, \"Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buck ML, Wiest D, Gillette PC, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Atenolol in Children,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1989, 46(6):629-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/2598566 /pubmed\" id=\"2598566 \" target=\"_blank\">",
"        2598566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Case CL, Trippel DL, and Gillette PC, &ldquo;New Antiarrhythmic Agents in Pediatrics,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1989, 36(5):1293-320.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/2508047/pubmed\" id=\"2508047\" target=\"_blank\">",
"        2508047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/12748199 /pubmed\" id=\"12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gold MH, Holy AK, and Roenigk HH Jr, \"Beta-Blocking Drugs and Psoriasis. A Review of Cutaneous Side Effects and Retrospective Analysis of Their Effects on Psoriasis,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1988, 19(5 Pt 1):837-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/2903871/pubmed\" id=\"2903871\" target=\"_blank\">",
"        2903871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, \"Psoriasis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(18):1899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trippel DL and Gillette PC, &ldquo;Atenolol in Children With Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1989, 64(3):233-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/2741832/pubmed\" id=\"2741832\" target=\"_blank\">",
"        2741832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trippel DL and Gillette PC, &ldquo;Atenolol in Children With Ventricular Arrhythmias,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1990, 119(6):1312-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/58/34726/abstract-text/2353617/pubmed\" id=\"2353617\" target=\"_blank\">",
"        2353617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12848 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34726=[""].join("\n");
var outline_f33_58_34726=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6172803\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137426\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137427\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051225\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051219\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137398\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137382\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051229\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051228\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137486\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137483\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051234\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051218\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051217\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298790\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137391\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137394\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137409\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051224\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051216\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051232\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051233\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051223\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1051235\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137404\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=related_link\">",
"      Atenolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/27/2486?source=related_link\">",
"      Atenolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34727="Lichen planus wrists fair skin";
var content_f33_58_34727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76383%7EDERM%2F63590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76383%7EDERM%2F63590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous polygonal papules are present on the ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous and hyperpigmented polygonal papules are present on ankles and ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34727=[""].join("\n");
var outline_f33_58_34727=null;
var title_f33_58_34728="Treatment options for locally advanced cholangiocarcinoma";
var content_f33_58_34728=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment options for locally advanced cholangiocarcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Christopher D Anderson, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Keith E Stuart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34728/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/58/34728/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholangiocarcinomas are rare malignancies arising from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Locally advanced, unresectable cholangiocarcinoma encompasses a heterogeneous mix of patients who fit the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macroscopic residual disease following resection",
"     </li>",
"     <li>",
"      Locally advanced, categorically unresectable disease at presentation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Criteria for resectability'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Locally recurrent disease after potentially curative treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local therapy may be considered either to increase the cure rate from surgery (in the setting of microscopically positive margins) or to relieve local symptoms such as pain or jaundice.",
"   </p>",
"   <p>",
"    Local treatment options for locally advanced, nonmetastatic cholangiocarcinoma will be reviewed here. Epidemiology, pathology, classification, staging, clinical presentation, diagnosis, and surgical therapy for localized potentially resectable disease, adjuvant therapy, and systemic therapy for advanced disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTINEOPLASTIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radiation therapy and chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy with or without concomitant chemotherapy is commonly offered to patients who have either microscopic or macroscopic residual disease following resection, as well as to those with symptomatic, locally unresectable or recurrent cholangiocarcinoma.",
"   </p>",
"   <p>",
"    Approaches to radiotherapy include external beam irradiation (EBRT) delivered either by conventional approaches or with conformal treatment planning techniques, brachytherapy with iridium-192, and stereotactic radiotherapy. With brachytherapy, thin wires of Ir-192 are introduced into the bile ducts via a catheter; these deliver high dose radiation to the tumors but very low doses to surrounding tissue. Stereotactic body radiotherapy is a form of EBRT in which high dose fractions of radiation precisely administered using a stereotactic frame of reference. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Microscopically positive margins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite uncertainty as to its survival benefit, postoperative adjuvant therapy is widely recommended for patients with microscopic residual disease following resection by expert groups, including the National Comprehensive Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This subject is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Adjuvant therapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Locally unresectable and recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 50 and 90 percent of patients with cholangiocarcinoma present with locally unresectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/3\">",
"     3",
"    </a>",
"    ]. The prognosis for patients with locally unresectable or locally recurrent disease is typically measured in months, and their lives are characterized by rapid decline with symptoms of progressive biliary obstruction. The goals of palliative therapy are relief of symptoms (pain, pruritus, jaundice) and improvement in quality of life.",
"   </p>",
"   <p>",
"    There is no role for tumor debulking in these cases. Conventional dose EBRT (with or without systemic chemotherapy) may relieve pain and contribute to biliary decompression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. At one year, 60 to 75 percent of patients are free of locoregional disease progression, and median survival approximates 7 to 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. However, local failure remains the first site of disease progression in 50 to 75 percent of cases.",
"   </p>",
"   <p>",
"    Higher dose RT approaches that use either a combination of transcatheter brachytherapy plus EBRT, three-dimensional conformal radiation therapy (3D-CRT), or intensity modulated radiation therapy (IMRT) with or without chemotherapy may be associated with better local control and possibly prolonged survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/9-21\">",
"     9-21",
"    </a>",
"    ]. As an example, in a series of 128 patients with unresectable hepatobiliary malignancies (46 with cholangiocarcinoma), 3D-CRT (median dose 60.75 Gy in twice daily 1.5 Gy fractions) directed only to the liver abnormalities was combined with concurrent intrahepatic artery",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/21/39253?source=see_link\">",
"     floxuridine",
"    </a>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/19\">",
"     19",
"    </a>",
"    ]. Sixty percent of all patients were free of hepatic progression at three years, and the median survival was 13.3 months.",
"   </p>",
"   <p>",
"    Technical advances over the past few years have created the ability to deliver more precise, highly conformal radiation treatment to a tumor, maximally sparing adjacent normal tissues. The enhanced capability to spare such normal tissues now permits the safe delivery of a single or limited number of high dose radiation fractions to a target, whereas in the past, small fractions of daily radiation were typically used to spare normal tissues. Approaches such as these are referred to as stereotactic body radiotherapy or stereotactic body radiosurgery, although many current approaches no longer utilize an external stereotactic localization method. Other names that have been applied to this approach include extracranial radiosurgery and extracranial radiotherapy. (\"Stereotactic body radiation therapy: Rationale and clinical experience\").",
"   </p>",
"   <p>",
"    Experience is limited. One report included 27 patients with unresectable cholangiocarcinoma who underwent stereotactic body radiotherapy (45 Gy in three fractions) as the sole form of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/22\">",
"     22",
"    </a>",
"    ]. At a median follow-up of 5.4 years, only two remained alive, and the median progression-free and overall survival were 6.7 and 10.6 months, respectively. While local control was maintained in 84 percent of patients at one year, six had severe",
"    <span class=\"nowrap\">",
"     duodenal/pyloric",
"    </span>",
"    ulceration and three developed duodenal stenosis.",
"   </p>",
"   <p>",
"    Importantly, no randomized trial has compared any of these newer radiotherapy techniques to conventional EBRT alone or fluoropyrimidine-based chemoradiotherapy using conventional fractionation. Furthermore, the possibility of higher rates of long-term toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/11,22\">",
"     11,22",
"    </a>",
"    ] has tempered enthusiasm for these approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Local ablation and embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with unresectable intrahepatic cholangiocarcinoma, nonsurgical methods of tumor ablation which may provide adequate local palliation include radiofrequency ablation, hepatic intraarterial chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/23\">",
"     23",
"    </a>",
"    ], and chemoembolization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/24\">",
"     24",
"    </a>",
"    ], and radioembolization using yttrium-90 [Y90]-tagged glass or resin microspheres that are delivered selectively to the tumor via the hepatic artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/25\">",
"     25",
"    </a>",
"    ]. The vast majority of the data come from combined series with predominantly hepatocellular carcinoma. These methods and results are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link\">",
"     \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT) involves the injection of an intravenous porphyrin photosensitizer followed by the endoscopic application of light (of a specific wavelength) to the tumor bed. The interaction between light and the photoagent causes tumor cell death, presumably by the generation of oxygen free radicals.",
"   </p>",
"   <p>",
"    Experience with PDT in cholangiocarcinoma is accumulating. Initial uncontrolled series suggested that, in addition to facilitating biliary decompression in patients with locally advanced disease, survival might be improved in patients who underwent PDT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/26-32\">",
"     26-32",
"    </a>",
"    ]. These favorable early results prompted two randomized trials, both of which suggest a survival benefit for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first, 19 patients with advanced cholangiocarcinoma were randomly assigned to stenting alone or followed by PDT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/33\">",
"       33",
"      </a>",
"      ]. The trial was stopped prematurely when patients undergoing PDT were found to have a significantly longer survival (median 493 versus 98 days), in addition to improved biliary drainage and quality of life.",
"     </li>",
"     <li>",
"      Similar outcomes were found in the second trial in which 32 patients with unresectable bile duct cancer were randomly assigned to PDT versus placement of a stent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/31\">",
"       31",
"      </a>",
"      ]. Nine of the 16 patients assigned to PDT required a second session, while one was treated a third time. Four weeks after treatment, most patients in the PDT group had almost complete elimination of bile duct stenosis in the treated area. The median survival after randomization was significantly longer in the PDT group (21 versus 7 months). PDT was complicated by prolonged cholangitis in three patients (which could be managed by antibiotic treatment) and cholecystitis in one.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is thought that the survival benefit is related to prolonged relief of obstruction rather than to any reduction in tumor mass. Although the factors that are associated with prolonged survival are not completely known, at least some data suggest that the absence of a visible mass on radiographic studies correlates with longer survival after PDT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main complication of PDT is cholangitis and liver abscess. PDT is now being studied preoperatively as a means of improving the likelihood of achieving a margin-negative resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/35\">",
"     35",
"    </a>",
"    ]. Unfortunately, treatment is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several chemotherapy regimens are active for treatment of advanced cholangiocarcinoma. Although most patients will be treated with the goal of palliation, a few selected patients with a borderline resectable intrahepatic cholangiocarcinoma will have a sufficient response to a regimen such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    to permit later resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Orthotopic liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic liver transplantation (OLT) has been evaluated as a treatment for intrahepatic and hilar cholangiocarcinomas with mixed results. In many cases, the patients were transplanted for primary sclerosing cholangitis (PSC), and they were found to have incidental cholangiocarcinomas in their native liver. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Orthotopic liver transplantation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=see_link\">",
"     \"Treatment of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interest in OLT as a treatment for cholangiocarcinoma has been revived by the published experience of the Mayo Clinic, which reported a five-year survival rate of 82 percent in a series of patients with initially unresectable cholangiocarcinoma arising in the setting of PSC who were treated with preoperative chemoradiotherapy followed by exploratory laparotomy to exclude metastatic disease before transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/36\">",
"     36",
"    </a>",
"    ]. While these results are encouraging, given the highly selected nature of these patients (and the fact that the results do not reflect an \"intent to treat\" analysis), the poor prognosis of the majority of patients with unresectable cholangiocarcinoma, and issues with donor allocation, OLT cannot be considered a standard form of therapy for locally unresectable cholangiocarcinoma at present. It should only be considered for highly selected patients with early stage unresectable hilar disease who have successfully completed rigorous staging and neoadjuvant therapy, preferably in the setting of a clinical research protocol. Such clinical protocols are available at only a few transplant centers. This subject is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Orthotopic liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary and guidelines from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal approach to patients with locally advanced unresectable or recurrent cholangiocarcinoma remains uncertain. For most patients, we suggest the use of 5-FU-based chemoradiotherapy with conventional fractionation external beam radiation therapy. Conformal treatment planning is preferred if it is available.",
"   </p>",
"   <p>",
"    Guidelines are available from two expert groups, the NCCN and ESMO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     NCCN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Updated guidelines for treatment of patients with unresectable cholangiocarcinoma from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370849\">",
"    <span class=\"h4\">",
"     Extrahepatic cholangiocarcinoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with locally advanced unresectable disease, options include a clinical trial, fluoropyrimidine-based chemoradiotherapy, fluoropyrimidine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based chemotherapy, or supportive care.",
"     </li>",
"     <li>",
"      For patients with resected, margin-positive disease, fluoropyrimidine-based chemoradiotherapy should be considered followed by additional fluoropyrimidine-based or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based chemotherapy, or if the nodes are positive, fluoropyrimidine-based or gemcitabine-based chemotherapy alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6370856\">",
"    <span class=\"h4\">",
"     Intrahepatic cholangiocarcinoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with locally advanced unresectable disease, options include a clinical trial, fluoropyrimidine-based chemoradiotherapy, fluoropyrimidine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based chemotherapy, or supportive care.",
"     </li>",
"     <li>",
"      For patients with positive margins (microscopic or macroscopic), options include reresection, ablation, or fluoropyrimidine chemoradiation or chemotherapy with a fluoropyrimidine-based regimen or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     ESMO",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the European Society of Medical Oncology (ESMO) include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For postoperative treatment after a noncurative resection of an intrahepatic or extrahepatic cholangiocarcinoma, supportive care alone, chemotherapy alone, and radiotherapy with or without chemotherapy are acceptable options.",
"     </li>",
"     <li>",
"      For unresectable cholangiocarcinomas, options include photodynamic therapy (with chemotherapy if a large mass is visible radiographically), palliative chemotherapy alone or concurrent chemoradiotherapy. Liver transplantation should not be offered outside of the scope of a clinical trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PALLIATION OF OBSTRUCTIVE JAUNDICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliation of jaundice can be accomplished by operative biliary-enteric bypass or by",
"    <span class=\"nowrap\">",
"     endoscopic/percutaneous",
"    </span>",
"    stenting of the biliary tree.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliative surgical bypass is typically only performed during an unsuccessful attempt at resection. Rarely, surgical bypass may be necessary in a jaundiced patient for whom stenting cannot be achieved for technical reasons such as tumor location.",
"   </p>",
"   <p>",
"    Most often, the bypass is to the liver segment",
"    <span class=\"nowrap\">",
"     IV-II/III",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ) bile duct. In some cases, bypass to the segment V duct (",
"    <a class=\"graphic graphic_figure graphicRef81897 \" href=\"mobipreview.htm?13/35/13878\">",
"     figure 1",
"    </a>",
"    ) can be used for palliation of the right liver ductal system but is performed less frequently due to higher technical difficulty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement of a stent is generally preferred for long-term palliation since it is associated with similar rates of successful palliation and survival but less morbidity compared to the surgical approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/37-44\">",
"     37-44",
"    </a>",
"    ]. Nevertheless, successful endoscopic deployment of a stent (or multiple stents as needed to span the malignant stricture) is possible in 70 to 100 percent of patients.",
"   </p>",
"   <p>",
"    Among the major issues are the optimal approach to stent placement, extent of decompression that is necessary to restore sufficient bile flow while avoiding the risk of bacterial cholangitis, the optimal approach to placement of the stents, and the use of plastic or metal (and bare versus covered) stents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718231662\">",
"    <span class=\"h3\">",
"     Percutaneous versus endoscopic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective series and at least two trials conducted in patients with obstructive jaundice from a malignant hilar obstruction (mainly proximal cholangiocarcinomas or gallbladder cancer) suggest that successful palliation of jaundice is more likely, and rates of early cholangitis may be lower with percutaneous as compared to endoscopic approach to biliary drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other complications may be more frequent (eg, bile leaks and bleeding), potentially increasing morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/46,48\">",
"     46,48",
"    </a>",
"    ]. Furthermore, percutaneous stents are usually left to open drainage external to the body, at least initially, and this is often inconvenient to the patient. As a result, in most institutions, an initial endoscopic attempt at drainage is usually preferred, if possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Unilateral versus bilateral stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with hilar obstruction, whether to use unilateral or bilateral stents is debated. In many cases, unilateral stent placement will be adequate because only 25 to 30 percent of the liver needs to be drained to relieve jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/49\">",
"     49",
"    </a>",
"    ]. However, unilateral drainage alone may not relieve jaundice completely and may increase the risk of cholangitis.",
"   </p>",
"   <p>",
"    Studies comparing these approaches have reached variable conclusions.",
"   </p>",
"   <p>",
"    Many endoscopists place bilateral stents (plastic or metal) when possible in an attempt to maximize biliary drainage. Preprocedure computed tomography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance cholangiopancreatography imaging is often used in an attempt to identify the dominant biliary system in the event that only one side can be drained endoscopically. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H17011729#H17011729\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Unilateral versus bilateral stenting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Plastic versus metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic biliary decompression can be achieved using either plastic or expandable metal stents. A variety of plastic and metal stents, both covered and uncovered, are available. A systematic review concluded that neither stent type offered a survival advantage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/50\">",
"     50",
"    </a>",
"    ]. As a result, the decision to use one versus another should be guided by expected length of survival, quality of life, costs, and physician expertise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H1135516949#H1135516949\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Types of stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The placement of a plastic stent is inexpensive and effective, and the stent can be easily removed or exchanged. Plastic stents, however, eventually develop occlusion by sludge",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacterial biofilm, and maintaining biliary drainage with plastic stents usually requires repeated endoscopic retrograde cholangiopancreatographies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H17011418#H17011418\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Patency of plastic stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metal stents extend the duration of stent patency (approximately 8 to 12 versus 2 to 5 months). However, metal stents have significantly higher costs and may not be removable. Thus, the diagnosis of malignant disease must be firmly established before a metal stent is deployed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H17011425#H17011425\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Plastic versus metal stents'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Plastic stents are often used to initially achieve drainage while the diagnostic work-up is ongoing or when a metal stent cannot be inserted for technical reasons. The high occlusion rate of plastic (polyethylene) stents (average 42 percent) can be reduced by changing the stents every three to six months. An alternative approach is to wait for a complication before changing the stent since many patients will die of their disease before their stents become obstructed. However, patients are at risk to develop cholangitis when the stent becomes obstructed. The preferred approach for patients who are expected to live beyond a few months is to replace the plastic stent with a metal one as soon as is feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718232158\">",
"    <span class=\"h3\">",
"     Covered versus uncovered stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have evaluated differences in stent patency rates between covered and uncovered metal stents for the treatment of distal malignant biliary disease; despite showing significantly less tumor ingrowth, patency rates are not higher for covered stents. This can likely be explained by the many other etiologies of stent occlusion other than tumor ingrowth, including tumor overgrowth and stent obstruction by debris and biliary sludge. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H1135517058#H1135517058\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H7922550#H7922550\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Covered versus uncovered metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the treatment of distal malignant biliary obstruction, many endoscopists place uncovered metal stents in patients with an intact gallbladder. For patients who have undergone prior cholecystectomy, the choice of covered versus uncovered stents is individualized given the location and geometry of the stenosis. Patients with extrinsic compression may be adequately treated with an uncovered stent, while those with intrinsic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    papillary tumors may benefit from a covered stent in an attempt to minimize tumor ingrowth. Covered metal stents are only used for distal biliary strictures because with hilar tumors, deployment may inadvertently result in occlusion of a major hepatic duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics have been examined as a means of reducing rates of stent occlusion among patients with indwelling stents. Two early trials, and a pooled analysis of both did not demonstrate any advantage in terms of stent occlusion, and they are not recommended for all patients who have an indwelling stent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H17011418#H17011418\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Patency of plastic stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, benefit in terms of lower rates of cholangitis was suggested in a randomized trial in which 94 patients with a plastic stent for palliation of malignant jaundice (mainly due to pancreatic cancer) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34728/abstract/51\">",
"     51",
"    </a>",
"    ]. Although there was no significant difference in long-term patency (as was seen in the other trials), patients who received prophylactic ciprofloxacin had significantly fewer episodes of cholangitis (23 versus 42 percent), and better quality of life.",
"   </p>",
"   <p>",
"    Based upon these data, we routinely use prophylactic antibiotics to reduce rates of cholangitis in patients receiving an endoscopically placed plastic or metal stent for long-term palliation of obstructive jaundice after the first episode of cholangitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally advanced, unresectable cholangiocarcinoma encompasses a heterogeneous mix of patients who fit the following categories (see",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macroscopic residual disease following resection",
"     </li>",
"     <li>",
"      Locally advanced, categorically unresectable disease at presentation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\", section on 'Criteria for resectability'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Locally recurrent disease after potentially curative treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following represents our general approach to treatment of locally advanced or recurrent cholangiocarcinoma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with intrahepatic or extrahepatic cholangiocarcinomas and macroscopic disease remaining after resection, we suggest treatment with fluoropyrimidine-based chemoradiotherapy using conventional dose external beam radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Conformal treatment planning is preferred if it is available. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radiation therapy and chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For extrahepatic cholangiocarcinomas, we suggest following chemoradiotherapy with additional fluoropyrimidine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Photodynamic therapy is emerging as an important palliative option for patients with locally advanced unresectable cholangiocarcinoma, although it is not widely available. For patients with locally advanced unresectable or recurrent disease, we recommend photodynamic therapy rather than stenting alone, where available (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Photodynamic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluoropyrimidine-based chemoradiotherapy as described above is appropriate where photodynamic therapy is not available. Rarely, patients with large unresectable tumors who are treated with chemoradiotherapy are converted to potentially resectable disease, and resection could be considered in this setting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Locally unresectable and recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unresectable intrahepatic cholangiocarcinoma, nonsurgical methods of tumor ablation which may provide adequate local palliation include radiofrequency or microwave ablation, transarterial chemoembolization, or radioembolization. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=see_link\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=see_link\">",
"       \"Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not recommend orthotopic liver transplantation as a standard form of therapy for cholangiocarcinoma outside of the context of a clinical research protocol (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Orthotopic liver transplantation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For palliation of jaundice in patients who have unresectable cholangiocarcinoma that is established either radiographically or laparoscopically, we recommend the placement of an endoscopically placed stents rather than surgical bypass (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Stenting'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although there may be some advantages to percutaneous rather than endoscopic placement, at most institutions, an initial endoscopic attempt at drainage is usually preferred. (See",
"      <a class=\"local\" href=\"#H718231662\">",
"       'Percutaneous versus endoscopic approach'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link\">",
"       \"Endoscopic stenting for malignant pancreaticobiliary obstruction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In contrast, for those who are found to have unresectable hilar cholangiocarcinoma during an exploratory laparotomy, we recommend biliary-enteric surgical bypass rather than endoscopic stenting to relieve jaundice (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Surgical bypass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylactic antibiotics after the first episode of cholangitis to reduce rates of cholangitis in patients who have an endoscopically placed plastic or metal stent for long-term palliation of obstructive jaundice (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/2\">",
"      Eckel F, Jelic S, ESMO Guidelines Working Group. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/3\">",
"      Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/4\">",
"      Whittington R, Neuberg D, Tester WJ, et al. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995; 13:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/5\">",
"      Ohnishi H, Asada M, Shichijo Y, et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology 1995; 42:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/6\">",
"      Park JY, Park SW, Chung JB, et al. Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer. Am J Clin Oncol 2006; 29:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/7\">",
"      Crane CH, Macdonald KO, Vauthey JN, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002; 53:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/8\">",
"      Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/9\">",
"      Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994; 28:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/10\">",
"      Foo ML, Gunderson LL, Bender CE, Buskirk SJ. External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 1997; 39:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/11\">",
"      Gerhards MF, van Gulik TM, Gonz&aacute;lez Gonz&aacute;lez D, et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003; 27:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/12\">",
"      Vallis KA, Benjamin IS, Munro AJ, et al. External beam and intraluminal radiotherapy for locally advanced bile duct cancer: role and tolerability. Radiother Oncol 1996; 41:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/13\">",
"      Minsky BD, Kemeny N, Armstrong JG, et al. Extrahepatic biliary system cancer: an update of a combined modality approach. Am J Clin Oncol 1991; 14:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/14\">",
"      Robertson JM, Lawrence TS, Dworzanin LM, et al. Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 1993; 11:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/15\">",
"      Robertson JM, Lawrence TS, Andrews JC, et al. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 1997; 37:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/16\">",
"      Kamada T, Saitou H, Takamura A, et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 1996; 34:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/17\">",
"      Kuvshinoff BW, Armstrong JG, Fong Y, et al. Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 1995; 82:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/18\">",
"      Shin HS, Seong J, Kim WC, et al. Combination of external beam irradiation and high-dose-rate intraluminal brachytherapy for inoperable carcinoma of the extrahepatic bile ducts. Int J Radiat Oncol Biol Phys 2003; 57:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/19\">",
"      Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005; 23:8739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/20\">",
"      Baisden JM, Kahaleh M, Weiss GR, et al. Multimodality Treatment With Helical Tomotherapy Intensity Modulated Radiotherapy, Capecitabine, and Photodynamic Therapy is Feasible and Well Tolerated in Patients With Hilar Cholangiocarcinoma. Gastrointest Cancer Res 2008; 2:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/21\">",
"      Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006; 20:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/22\">",
"      Kopek N, Holt MI, Hansen AT, H&oslash;yer M. Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol 2010; 94:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/23\">",
"      Kim JH, Yoon HK, Sung KB, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008; 113:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/24\">",
"      Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011; 117:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/25\">",
"      Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/26\">",
"      Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/27\">",
"      Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006; 244:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/28\">",
"      Dumoulin FL, Gerhardt T, Fuchs S, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/29\">",
"      Wiedmann M, Berr F, Schiefke I, et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 2004; 60:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/30\">",
"      Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/31\">",
"      Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/32\">",
"      Gao F, Bai Y, Ma SR, et al. Systematic review: photodynamic therapy for unresectable cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2010; 17:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/33\">",
"      Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/34\">",
"      Prasad GA, Wang KK, Baron TH, et al. Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol 2007; 5:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/35\">",
"      Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 2003; 97:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/36\">",
"      Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/37\">",
"      Washburn WK, Lewis WD, Jenkins RL. Aggressive surgical resection for cholangiocarcinoma. Arch Surg 1995; 130:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/38\">",
"      Pichlmayr R, Weimann A, Klempnauer J, et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996; 224:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/39\">",
"      Benjamin IS. Surgical possibilities for bile duct cancer: standard surgical treatment. Ann Oncol 1999; 10 Suppl 4:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/40\">",
"      Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/41\">",
"      Shepherd HA, Royle G, Ross AP, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/42\">",
"      Lai EC, Chu KM, Lo CY, et al. Choice of palliation for malignant hilar biliary obstruction. Am J Surg 1992; 163:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/43\">",
"      Andersen JR, S&oslash;rensen SM, Kruse A, et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/44\">",
"      Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998; 42:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/45\">",
"      Saluja SS, Gulati M, Garg PK, et al. Endoscopic or percutaneous biliary drainage for gallbladder cancer: a randomized trial and quality of life assessment. Clin Gastroenterol Hepatol 2008; 6:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/46\">",
"      Pi&ntilde;ol V, Castells A, Bordas JM, et al. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprostheses for treating malignant biliary obstruction: randomized clinical trial. Radiology 2002; 225:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/47\">",
"      Paik WH, Park YS, Hwang JH, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/48\">",
"      Speer AG, Cotton PB, Russell RC, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/49\">",
"      Dowsett JF, Vaira D, Hatfield AR, et al. Endoscopic biliary therapy using the combined percutaneous and endoscopic technique. Gastroenterology 1989; 96:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/50\">",
"      Levy MJ, Baron TH, Gostout CJ, et al. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin Gastroenterol Hepatol 2004; 2:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34728/abstract/51\">",
"      Chan G, Barkun J, Barkun AN, et al. The role of ciprofloxacin in prolonging polyethylene biliary stent patency: a multicenter, double-blinded effectiveness study. J Gastrointest Surg 2005; 9:481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2497 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34728=[""].join("\n");
var outline_f33_58_34728=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTINEOPLASTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radiation therapy and chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Microscopically positive margins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Locally unresectable and recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Local ablation and embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Orthotopic liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary and guidelines from expert groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - NCCN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6370849\">",
"      Extrahepatic cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6370856\">",
"      Intrahepatic cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - ESMO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PALLIATION OF OBSTRUCTIVE JAUNDICE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718231662\">",
"      - Percutaneous versus endoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Unilateral versus bilateral stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Plastic versus metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718232158\">",
"      - Covered versus uncovered stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2497\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2497|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/35/13878\" title=\"figure 1\">",
"      Segmental anatomy of liver",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/18/36138?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Radiofrequency ablation, percutaneous ethanol injection, thermal ablation, and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/9/41114?source=related_link\">",
"      Nonsurgical therapies for localized hepatocellular carcinoma: Transarterial embolization, radiotherapy, and radioembolization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41097?source=related_link\">",
"      Treatment of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34729="Urticaria annular lesions";
var content_f33_58_34729=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60454%7EDERM%2F63996%7EALLRG%2F77506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60454%7EDERM%2F63996%7EALLRG%2F77506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular, edematous, mildly erythematous plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple mildly erythematous and edematous plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 247px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34729=[""].join("\n");
var outline_f33_58_34729=null;
var title_f33_58_34730="Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors";
var content_f33_58_34730=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tyrosine kinase inhibitor therapy for advanced gastrointestinal stromal tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     George D Demetri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Jeffrey Morgan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/58/34730/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/58/34730/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a striking evolution in how they are perceived and classified over the last 30 years. A significant breakthrough occurred with the identification of near-universal expression of the CD117 antigen by these tumors (now called gastrointestinal stromal tumors or GISTs). The other group of spindle cell neoplasms arising in the GI tract (which are analogous to soft tissue tumors throughout the rest of the body and include lipomas, schwannomas, hemangiomas, usual leiomyomas and the malignant counterpart, leiomyosarcomas) is typically CD117-negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CD117 molecule is part of the KIT (c-kit) receptor, a membrane tyrosine kinase (TK) that is a product of the KIT protooncogene. In 80 percent of cases, KIT overexpression is the result of an activating mutation in the KIT protooncogene. Although the majority of GISTs are KIT positive, some KIT-negative GISTs have activating mutations in a related TK receptor, platelet-derived growth factor receptor alpha (PDGFRA). The current view is that the overwhelming majority of GI tract mesenchymal tumors fall into the GIST category; they are identifiable by KIT immunoreactivity or the presence of activating mutations in KIT or PDGFRA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Classification and molecular pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the year 2000, there was no known effective therapy for unresectable or metastatic GISTs. It has long been appreciated that GI tract sarcomas have lower response rates to chemotherapy than other sites of soft tissue sarcomas, indicating a higher rate of primary resistance to chemotherapy in these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of GISTs was revolutionized by the finding that mutational activation of KIT or PDGFRA stimulated growth of these cancer cells. This led to effective systemic therapies in the form of small molecule inhibitors of the receptor TKs.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    (Gleevec), the prototype drug, was originally approved for the treatment of chronic myeloid leukemia (CML), a disorder in which an aberrant TK results from molecular rearrangement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It subsequently became evident that molecularly targeted therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    induced dramatic, rapid, and sustained clinical benefit in GISTs as well. These agents block signaling via KIT or PDGFRA by binding to the ATP-binding pocket required for phosphorylation and activation of the receptor. Other TK inhibitors (TKIs) have been identified that block several TK targets, including KIT (referred to as multitargeted TKIs). Some data suggest an anti-GIST immune response is associated with good clinical outcomes in patients with GIST on imatinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Here we will discuss TKI therapy for patients with",
"    <span class=\"nowrap\">",
"     advanced/metastatic",
"    </span>",
"    GISTs. Molecular classification, clinical presentation, diagnosis, management of localized GISTS, the role of surgery in patients with metastatic disease, and the use of preoperative as well as adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    are addressed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=see_link\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY OF IMATINIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the initial report of a patient with rapidly progressive GIST who exhibited a dramatic and sustained response within one month of starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/6\">",
"     6",
"    </a>",
"    ], many studies have confirmed the utility of this agent in advanced disease (",
"    <a class=\"graphic graphic_table graphicRef78415 \" href=\"mobipreview.htm?19/44/20172\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II study, for example, 147 patients received either 400 or 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      daily; 54 percent had radiographic responses documented within six months, with no significant difference between the two doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/8\">",
"       8",
"      </a>",
"      ]. PET scanning proved to be a sensitive and reliable response indicator, with markedly diminished uptake, compared to baseline studies, seen in responders as early as 24 hours after the first dose of imatinib. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessing response to therapy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Adverse events were common but generally mild. These included grade 1 or 2 nausea or diarrhea in approximately one-half, fluid retention (predominantly periorbital) in three-fourths, muscle cramps and fatigue (40 and 35 percent, respectively), and gastrointestinal or intraabdominal hemorrhage in 5 percent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Side effects and their management'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      A sizeable subset of patients in this trial survived long-term on first-line imatinib. In a preliminary report of long-term follow-up of a cohort of 56 patients who continued to take imatinib beyond three years, 26 (18 percent of the initial cohort) remained on continuous imatinib since study entry at a median follow-up of 9.4 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/12\">",
"       12",
"      </a>",
"      ]. The overall likelihood of remaining progression-free at nine years or beyond was dependent on tumor size at initial diagnosis and ranged from 29 percent in those with an initial tumor bulk of &lt;39.1 mm",
"      <sup>",
"       2",
"      </sup>",
"      to 3 percent in those with an initial tumor bulk &gt;262.6 mm",
"      <sup>",
"       2",
"      </sup>",
"      . The corresponding rates of overall survival were 58 and 23 percent, respectively.",
"     </li>",
"     <li>",
"      Following the introduction of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , the median survival of patients with advanced GIST increased from an average of 18 to 57 months in the trial with the longest follow-up to date [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite the high efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in most patients with",
"      <span class=\"nowrap\">",
"       metastatic/inoperable",
"      </span>",
"      GISTs, complete responses are rare overall (less than 10 percent), and most patients who initially respond eventually acquire resistance via additional mutations in KIT, discussed below. The median time to progression is approximately two to three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/8,10,14,15\">",
"       8,10,14,15",
"      </a>",
"      ], although it is longer in some series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/16\">",
"       16",
"      </a>",
"      ]. Factors influencing the duration of disease control are not well understood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management of refractory or intolerant patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Assessing response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal method for establishing response to TKIs like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is evolving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     PET scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET scans appear to identify a greater number of responses and at an earlier time than CT scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. With functional imaging such as PET, responses can be observed within 24 hours of starting therapy. In addition to early identification of primary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance, PET can also aid in the detection of secondary resistance. A rigorous standardized approach to patient preparation and study technique is needed for reproducible results, as emphasized by consensus guidelines on use of FDG-PET for response assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the added benefit for dual modality",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging in most cases with advanced GIST is unclear, and PET scans are rarely used to assess the response to therapy in patients with advanced disease, unless in the context of a clinical trial. &nbsp;Newly proposed CT criteria using either no growth in tumor size or a combination of tumor density and size criteria have shown a close correlation with the predictive value results of FDG-PET, and serial CT scanning at three to four month intervals is more often recommended during therapy (see",
"    <a class=\"local\" href=\"#H6\">",
"     'RECIST versus CHOI criteria'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    However, one clinical scenario where baseline and follow-up PET scan might prove useful is for a patient with a borderline resectable GIST or a potentially resectable tumor that requires extensive organ disruption who is being treated with initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. In these situations, early assessment of treatment response provides the opportunity to shift to an alternative therapy (eg, resection or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ) if imatinib is ineffective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link\">",
"     \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Conventional CT scans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographically, GISTs may actually increase in size during early treatment as a consequence of intratumoral hemorrhage or myxoid degeneration. A decrease in tumor density as seen on CT (the corollary of decreased FDG uptake on PET, see above) is an important early clinical marker of antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Once tumors become hypodense (cystic), the size of the lesions may decrease slowly and eventually stabilize.",
"   </p>",
"   <p>",
"    Late responses are often seen in patients who initially have stable disease, and survival in those with stable disease parallels that of patients with an objective response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. The median time to achieve an objective response is four months, while maximal response may take six months or even longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these issues, response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    is frequently defined as absence of progression at the time of the first formal disease reevaluation (typically two to three months after starting therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/27\">",
"     27",
"    </a>",
"    ]. Clear cut evidence of progression at this time point is considered initial (primary) resistance, while progression or relapse after a period of stable or responding disease is referred to as late (secondary) resistance. Initial resistance was seen in 12 percent of 934 patients in a randomized European trial exploring two different doses of imatinib (discussed below) and was more likely in patients with lung but not liver metastases (41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/14\">",
"     14",
"    </a>",
"    ]. The management of patients with imatinib-refractory disease is discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Management of refractory or intolerant patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     RECIST versus CHOI criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, radiographic response to TKIs is often indicated by an early decrease in tumor density, followed by slow tumor regression. This pattern of response is not well suited to the use of standard RECIST (Response Evaluation Criteria In Solid Tumors), which is based upon tumor measurements (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Likewise, disease progression in patients with GIST may also fail to be captured by standard RECIST. Tumor progression may manifest as new or enlarging tumor masses, as partial to complete filling-in of a previously hypodense lesion, or as a hyperdense \"nodule-within-a-mass\" pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/30\">",
"     30",
"    </a>",
"    ]. The importance of identifying this latter situation is that successful ablation of such resistant clones has been reported, with continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    sensitivity of areas of disease that remain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative set of response evaluation criteria has been proposed, the so-called Choi criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Investigators at M D Anderson initially showed that a 10 percent decrease in unidimensional tumor size or a 15 percent decrease in tumor density on contrast-enhanced CT scans (as reflected by differences in x-ray attenuation between a given material and water, expressed in Hounsfield units) correlates well with PET scan findings and is a better predictor of response to therapy (as judged by time to tumor progression) than standard RECIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These investigators compared the Choi criteria to standard (version 1.0, (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 2",
"    </a>",
"    )) RECIST in 98 patients (40 in a training set and 58 a test set) receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    for advanced GIST who had CT scans eight weeks after starting therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/33\">",
"     33",
"    </a>",
"    ]. The test set had 28 (48 percent) good responders by RECIST, compared to 49 (84 percent) good responders by Choi criteria. Even when the 98 patients were analyzed together, the response group by RECIST did not correlate significantly with either disease-specific survival or time to tumor progression, whereas the Choi response group did correlate with both endpoints. The authors concluded that tumor response for GIST should preferentially be categorized by the Choi rather than the RECIST.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Impact of dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two randomized trials have failed to show significantly greater efficacy for higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    doses (800 versus 400 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In both trials, patients with disease progression in the standard-dose arm were allowed to cross over to high-dose therapy. The European trial demonstrated a modestly but significantly higher PFS with the 800 mg dose with median 25 month follow-up, which was no longer evident with longer follow-up (median 40 months), and which did not lead to a significant improvement in overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/10\">",
"     10",
"    </a>",
"    ]. The American trial showed no advantage for higher dose therapy in terms of either PFS or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/11\">",
"     11",
"    </a>",
"    ]. Both trials indicated more side effects from higher-dose therapy.",
"   </p>",
"   <p>",
"    A meta-analysis of both trials came to the following conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a median follow-up of 45 months, a small but statistically significant PFS advantage was seen with higher dose therapy (hazard ratio [HR] for progression 0.89, 95% CI 0.79 to 1.0), but overall survival and best response (51 versus 54 percent) were similar.",
"     </li>",
"     <li>",
"      The presence of a KIT exon 9 mutation was the only significant predictive factor for benefit from higher doses. Among the patients with an exon 9 mutation, PFS (HR 0.58, 95% CI 0.38-0.91) and overall response rate (47 versus 21 percent) were significantly higher with high-dose therapy, but in the absence of such mutations, no difference was observed between the treatment arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pharmacokinetic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another possible explanation for the failure to demonstrate benefit from higher",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    doses in both trials is interpatient variability in pharmacokinetic exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 73 patients who were randomly assigned to 400 or 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      daily for advanced GIST, there was a 10-fold variance in trough levels with either dose (from 414 to 4182",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/35\">",
"       35",
"      </a>",
"      ]. Clinical outcomes were correlated with trough levels at steady state. Trough values below 1100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      were associated with a significantly shorter time to tumor progression and a lower rate of clinical benefit as compared to higher trough levels.",
"     </li>",
"     <li>",
"      Others have shown a significant correlation between low",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      trough levels and prior major gastrectomy, higher creatinine clearance, and high serum albumin levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pharmacokinetic variability may also contribute to acquired drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/37\">",
"     37",
"    </a>",
"    ]. In a small population-based pharmacokinetic study in patients with GIST,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    clearance increased after long-term treatment (&gt;one year), which reduced systemic exposure by 42 percent compared to the start of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/38\">",
"     38",
"    </a>",
"    ]. These findings were confirmed in a subsequent prospective population pharmacokinetic study of 50 patents with GIST being treated with imatinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/39\">",
"     39",
"    </a>",
"    ]. After 90 days of treatment, there was a significant decrease in imatinib exposure of 29 percent compared with baseline. However, there appeared to be no statistically significant effect of pharmacokinetic variability on progression-free survival in the subset of patients treated with imatinib for advanced incurable disease.",
"   </p>",
"   <p>",
"    It is not yet clear whether reduced",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    clearance is a significant factor in the amelioration of imatinib toxicity that occurs with time",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    has any impact on disease control; further work is required to ascertain the clinical implications of these observations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Influence of mutations on response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of mutation in KIT and PDGFRA correlates with clinical response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST\", section on 'Significance of tumor genotype and kinase mutation status'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This issue was addressed in a report of 127 patients with GISTs receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ; activating mutations in KIT and PDGFRA were found in 88 and 4.7 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/40\">",
"     40",
"    </a>",
"    ]. All KIT mutant isoforms were associated with a response to imatinib, while only a subset of PDGFRA mutants was imatinib-sensitive. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'PDGFRA mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Among the patients with KIT mutations, those with an exon 11 mutation had a substantially greater likelihood of a partial response compared to patients with either an exon 9 mutation or no detectable mutation in either KIT or PDGFRA (84 versus 48 and 0 percent, respectively), and a longer time to treatment failure as well.",
"   </p>",
"   <p>",
"    These results were confirmed in a larger series of 324 patients enrolled in the US Intergroup trial comparing two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients whose tumors expressed an exon 11 mutant isoform were more likely to have an objective response to imatinib compared to those with an exon 9 isoform or those who had no kinase mutations (72 versus 44 and 45 percent, respectively). Patients with an exon 11 mutation also had a significantly longer time to disease progression (25 versus 17 and 13 months, respectively) and median overall survival (median 60 versus 38 and 49 months, respectively).",
"   </p>",
"   <p>",
"    Data from this trial as well as an analysis of data from the randomized EORTC dose-response trial described above suggests that higher daily doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    may preferentially benefit those with exon 9 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In the 58 patients enrolled in the EORTC trial whose tumors expressed an exon 9 mutant KIT protein, an initial daily imatinib dose of 800 mg resulted in a significantly superior progression-free survival (hazard ratio for progression 0.39) compared to 400",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    In contrast, the time to progression was not affected by the initial dose in patients with an exon 11 KIT mutation or wild-type KIT. There were no corresponding differences in overall survival between low-dose and high-dose initial therapy in patients with exon 9 mutations. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Impact of dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Similar conclusions were reached in a meta-analysis that included patients treated on this trial as well as the American Intergroup trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/45\">",
"     45",
"    </a>",
"    ]. In a preliminary report, higher dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    preferentially benefited patients with exon 9 mutations in terms of PFS (at three-years, 25 versus 0 percent for 800 versus 400 mg daily, hazard ratio 0.43), but there was no survival advantage.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is approved in the US for the treatment of all KIT-expressing GISTs regardless of mutation status. More information is needed before mutation testing is adopted as part of the routine analysis of KIT-expressing GISTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/46\">",
"     46",
"    </a>",
"    ]. Exon 9 mutations are associated with a lower response rate, but overall survival does not appear to be better with high-dose therapy. Guidelines from the National Comprehensive Cancer Network (NCCN) recommend initiating therapy for unresectable or metastatic disease with imatinib 400 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/23\">",
"     23",
"    </a>",
"    ]. However, if molecular diagnosis is available and exon 9-positive, they support the use of imatinib at 800 mg daily. In contrast, ESMO recommends mutation testing for all patients and starting imatinib at 800 mg daily for exon 9 mutants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, where mutation testing is not routine, a common maneuver is to start with 400 mg daily, and increase the dose if there is no response. Initiation of second-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    is a reasonable alternative. Whether outcomes are better with early institution of sunitinib following progression on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    400 mg daily is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     PDGFRA mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 5 and 7 percent of GISTs are KIT-negative but many have detectable PDGFRA mutations.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    has demonstrable antitumor efficacy in some GIST tumors that lack KIT overexpression but presumably have mutations in the PDGFRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/11\">",
"     11",
"    </a>",
"    ], and in some non-GIST tumors that lack KIT mutations but are characterized by alterations in the PDGF pathway (such as desmoids and dermatofibrosarcoma protuberans). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=see_link\">",
"     \"Dermatofibrosarcoma protuberans\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=see_link&amp;anchor=H29#H29\">",
"     \"Head and neck sarcomas\", section on 'Desmoids and dermatofibrosarcoma protuberans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in GIST, not all activating mutations in PDGFRA are biologically equivalent. Some GIST PDGFRA mutations confer relative resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , while others are sensitive to this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/40,42,48,49\">",
"     40,42,48,49",
"    </a>",
"    ]. In one large series of 289 reported PDGFRA-mutant GISTs, 181 (63 percent) had the imatinib-resistant substitution D842V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/42\">",
"     42",
"    </a>",
"    ]. The clinical efficacy of imatinib in these patients was addressed in a subsequent survey series of 58 patients with PDGFRA-mutant GIST; none of the 31 with a D842V substitution responded to imatinib, and 21 (68 percent) had progression as their best response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/50\">",
"     50",
"    </a>",
"    ]. In contrast, among the 26 patients with non-D842V PDGFRA mutations, there were two complete and eight partial responses (overall response rate 39 percent).",
"   </p>",
"   <p>",
"    Although mutation screening may help in the management of these tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/42\">",
"     42",
"    </a>",
"    ], molecular analysis for the specific type of PDGFRA mutation is typically not carried out at most institutions. Because of this variability in response, patients with advanced GI stromal tumors that appear histologically compatible with a diagnosis of GIST should not be denied a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    if they are KIT-negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy for responding patients with",
"    <span class=\"nowrap\">",
"     advanced/metastatic",
"    </span>",
"    disease was addressed in a French trial that randomly assigned patients with advanced GIST and no disease progression after one year of imatinib to continuous treatment or interruption until disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/51\">",
"     51",
"    </a>",
"    ]. The study was stopped prematurely after only 58 patients had been randomized when it became evident that the risk of progression was significantly higher if therapy was interrupted, even in completely responding patients.",
"   </p>",
"   <p>",
"    Of the 32 patients who interrupted therapy, 26 progressed and needed retreatment, compared to only 8 of 26 in the continuous therapy arm (81 versus 31 percent). The corresponding median progression-free survival durations were 18 versus 6 months. There were no significant differences between the groups with respect to survival, incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance, or quality of life. Drug reintroduction achieved tumor control in 24 of 26 of the patients whose therapy was interrupted.",
"   </p>",
"   <p>",
"    A subset of 50 patients who remained free of progression after completing three years of therapy were again randomized to continue (n = 25) or discontinue therapy (n = 25) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/52\">",
"     52",
"    </a>",
"    ]. The two-year PFS was 16 and 80 percent in the groups who continued versus discontinued therapy; all patients who discontinued therapy regained tumor control after reintroduction of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . There was no evidence that treatment interruption increased the time to develop secondary resistance.",
"   </p>",
"   <p>",
"    Thus, interruption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    results in rapid progression in most patients with advanced GIST and cannot be recommended unless there is significant toxicity. Continuous therapy until disease progression (or lifelong if disease does not progress) is advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Side effects and their management",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    is generally well tolerated; most side effects are less than grade 2, and the majority of patients can continue treatment without interruption. In general, the side effect profile tends to improve with prolonged therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minimal data have been published on managing the side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/46\">",
"     46",
"    </a>",
"    ]. The most common side effects reported in GIST patients receiving imatinib are fluid retention, diarrhea, nausea, fatigue, muscle cramps, abdominal pain and rash. These and other potentially more severe but less common side effects and proposed management strategies are summarized below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid retention &ndash; Fluid retention with peripheral edema, and occasionally pleural effusion and ascites may be more common in older patients and in those with cardiac disease. Periorbital edema is more common and often does not respond to diuretics, but may improve with dietary salt restriction. It tends to be most prominent in the morning and decreases in intensity if the patient is upright during the day.",
"      <br/>",
"      <br/>",
"      In patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in National Cancer Institute (NCI)-sponsored trials, the rate of grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      edema considered likely related to imatinib was 1.3 percent.",
"     </li>",
"     <li>",
"      Muscle cramps &ndash; Muscle cramps are perhaps the most bothersome long-term symptom associated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , most commonly affecting calves, feet, and hands. There is no definitive treatment, although anecdotally some patients have obtained benefit from treatment with calcium or magnesium supplements, or the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Nausea, vomiting, dyspepsia &ndash; Nausea and vomiting are generally not a problem when the drug is taken with food, which does not diminish absorption. Dyspepsia and GI upset may also be lessened by taking the drug with meals. Symptomatic treatment with antacids or proton pump inhibitors may be needed.",
"     </li>",
"     <li>",
"      Abdominal discomfort, diarrhea &ndash; Flatulence and mild abdominal discomfort are common. Diarrhea is usually grade 1 to 2 but is occasionally more severe. Loose stools can usually be managed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      <span class=\"nowrap\">",
"       sulfate/diphenoxylate",
"      </span>",
"      hydrochloride.",
"     </li>",
"     <li>",
"      Rash &ndash; Skin rash is usually maculopapular and mild. It often resolves with continued treatment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H3#H3\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Acneiform eruption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematologic toxicity &ndash; Mild anemia is common with chronic use or higher doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/54\">",
"       54",
"      </a>",
"      ]. Treatment with erythropoietin may benefit the occasional patient with more severe anemia. Macrocytosis, with elevation of the mean corpuscular volume, is observed frequently; the mechanism is unknown.",
"      <br/>",
"      <br/>",
"      Neutropenia is rare. Patients may safely continue the drug as long as the absolute neutrophil count is &ge;1000",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      Withholding the drug usually leads to resolution of neutropenia, often within days. Reinitiation of the same drug dose is often accomplished without reoccurrence; dose reduction may be needed if the patient continues to experience significant neutropenia.",
"     </li>",
"     <li>",
"      Hypophosphatemia &ndash; Hypophosphatemia is reported, especially with higher doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/55,56\">",
"       55,56",
"      </a>",
"      ]. Routine monitoring of phosphate levels has been suggested by the manufacturer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gynecomastia &ndash; Gynecomastia was reported in 7 of 38 men receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      for chronic myeloid leukemia (CML) and associated with reduced levels of free testosterone. Gynecomastia is not yet reported in men receiving imatinib for GIST. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Management of side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung and liver toxicity &ndash; Lung toxicity and elevation of liver function tests (LFTs) have only occasionally been reported. Fatal hepatotoxicity was noted in a patient in blast crisis who was taking large doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      concurrently, and it is recommended that acetaminophen use be avoided, if possible. At least some data suggest that concomitant administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and corticosteroids may permit continued imatinib treatment in patients who develop LFT abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac toxicity &ndash; The issue of cardiac toxicity is unresolved. In 2006, there was a report of severe heart failure developing in 10 individuals receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , although the disease for which treatment was being given was not specified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/59\">",
"       59",
"      </a>",
"      ]. Subsequent experience suggests that among patients receiving imatinib for CML, there is a risk for heart failure, but the risk is fairly low and probably limited to those with preexisting heart disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Cardiovascular'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    causes cardiac toxicity in patients treated for GIST is unclear; the following information on this issue is available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from the EORTC study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      400 versus 800 mg noted no excess of clinical cardiac events in the study population who were treated for a median of 24 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Impact of dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A retrospective review of the M D Anderson experience of 129 patients enrolled in clinical trials of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      for GIST over a six-year period identified potential cardiac adverse events in 18 (8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/61\">",
"       61",
"      </a>",
"      ]. The adverse events included dyspnea, chest pain, edema, pleural effusion, ascites, cardiac ischemia and arrhythmia. Thirteen had risk factors for coronary artery disease or established heart disease. None of the patients had evidence of pulmonary vascular congestion on chest radiography. Of the eight patients who underwent echocardiography or radionuclide ventriculography, only one had a left ventricular ejection fraction &lt;50 percent. All patients were able to continue imatinib with dose adjustment and toxicity-specific management.",
"     </li>",
"     <li>",
"      In the landmark phase III placebo-controlled adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      trial, there was no excess of cardiotoxicity in the group that received one year of postoperative imatinib. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link&amp;anchor=H6#H6\">",
"       \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Phase III trials'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Until further information becomes available, the following actions would be prudent:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As part of the informed consent process, patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should be notified that heart failure may be a rare but potentially serious adverse event",
"     </li>",
"     <li>",
"      Patients currently taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should be monitored for signs and symptoms of left ventricular systolic dysfunction",
"     </li>",
"     <li>",
"      Heart failure should be considered in the differential diagnosis of any patient experiencing peripheral edema while receiving this agent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GI bleeding &ndash; Patients with large bulky tumors have a 5 percent risk of tumor hemorrhage not associated with thrombocytopenia. These patients should be closely monitored for a drop in hemoglobin in the first four to eight weeks of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/46\">",
"       46",
"      </a>",
"      ]. If the hemoglobin level acutely decreases &ge;2",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      should be temporarily withheld until blood counts have stabilized, with transfusion if needed. Emergent surgical intervention may be needed if bleeding does not resolve. However, emergency surgery is uncommonly needed. It was required in three of 232 patients in one report (1.3 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If life-threatening side effects develop that cannot be managed with maximal supportive care, a switch to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    should be considered. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Management of refractory or intolerant patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Non-GIST soft tissue sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    does not appear to be active in non-GIST soft tissue sarcomas, even if they express KIT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/53\">",
"     53",
"    </a>",
"    ]. Advanced leiomyosarcomas involving the gastrointestinal tract are usually treated with similar chemotherapy regimens as other advanced soft tissue sarcomas, although their pattern of response to individual regimens may be different from other sarcomas. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in patients with metastatic disease is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=see_link&amp;anchor=H15#H15\">",
"     \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Role of surgery in patients with metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF REFRACTORY OR INTOLERANT PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose escalation is an option for patients with primary as well as secondary (late) resistance to standard doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Patients who are intolerant of imatinib are better served by switching to an alternative TKI,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dose escalation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose escalation may be considered in patients started on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    400 mg daily who, after careful review of radiologic studies, are judged to have clear evidence of disease progression. The efficacy of this approach was shown in follow-up reports from both the American and European randomized dose-finding studies described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/11,63\">",
"     11,63",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Impact of dose'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the European study described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/10\">",
"       10",
"      </a>",
"      ], 247 of the 473 patients randomly assigned to low dose therapy progressed, and 133 were crossed over to higher dose therapy (400 mg twice daily) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/63\">",
"       63",
"      </a>",
"      ]. There were three confirmed partial responses, and 36 patients had prolonged periods of stable disease. Anemia and fatigue increased on the higher dose, but 18 percent were still alive and progression-free at one year.",
"     </li>",
"     <li>",
"      Similar results were noted in the American trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/11\">",
"       11",
"      </a>",
"      ]. Of the 164 patients progressing on low-dose therapy, 133 crossed over to 800 mg daily. Following crossover, 33 percent of assessable patients (n = 117) achieved either an objective response (n = 3) or stable disease (n = 20). The median durations of PFS and overall survival after crossover were 5 and 19 months, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increasing the dose is unlikely to benefit patients who progress rapidly (within two months) after starting therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25772305\">",
"    <span class=\"h2\">",
"     Alternative treatment strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emerging data suggest that selection of clones with secondary KIT mutations is the most common mechanism of secondary",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. Possible methods of overcoming imatinib resistance include the use of more powerful selective TKIs, multitargeted inhibitors, or combination therapies utilizing selective inhibitors of the TK receptor itself coupled with selective inhibitors of downstream pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasing number of reports indicate efficacy for the multi-targeted TKI",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (SU11248, Sutent) in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory or intolerant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/69-74\">",
"     69-74",
"    </a>",
"    ]. An international phase III trial of sunitinib versus placebo in 312 patients with refractory disease definitively established the role of sunitinib in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/72\">",
"     72",
"    </a>",
"    ]. Patients demonstrating progression (by original RECIST) while on placebo crossed over to the active treatment arm. In the latest update, at a median follow-up of 42 months, despite a low objective response rate in the sunitinib group (7 percent partial response), median time to tumor progression, the primary endpoint, was fourfold higher as compared to the placebo group (27 versus 6 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/74\">",
"     74",
"    </a>",
"    ]. Although survival was significantly better with sunitinib in the initial report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/72\">",
"     72",
"    </a>",
"    ], over time, as expected, overall survival converged (median 73 versus 65 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/74\">",
"     74",
"    </a>",
"    ]. The median number of weeks on treatment was 22.",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , the clinical activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    is significantly influenced by the specific mutation type. This was shown in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial performed in 97 patients with metastatic, imatinib-refractory or intolerant GISTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/71\">",
"     71",
"    </a>",
"    ]. Clinical benefit (partial response or stable disease for longer than six months) was significantly higher for those with a primary KIT 9 exon (58 percent) or wild-type",
"    <span class=\"nowrap\">",
"     KIT/PDGFRA",
"    </span>",
"    mutation (56 percent) than for those with a KIT exon 11 mutation (34 percent). The same pattern was seen for progression-free and overall survival. Following progression on imatinib, patients with KIT exon 9 mutation or a PDGFRA mutation had a median time to progression of 19 months, while for those with exon 11 mutations, it was only five months.",
"   </p>",
"   <p>",
"    There was also a correlation between secondary mutations and response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    . Both progression-free and overall survival were significantly longer for patients with secondary KIT exon 13 or 14 mutations than for those with exon 17 or 18 mutations (7.8 versus 2.3 months).",
"   </p>",
"   <p>",
"    As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , PET scans can permit an earlier assessment of response than conventional CT scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/70,75\">",
"     70,75",
"    </a>",
"    ], but are rarely used outside of the context of a clinical trial.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is approved in the US for the treatment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory or intolerant advanced GISTs. The approved dose is 50 mg daily for four of every six weeks. However, continuous daily dosing (37.5 mg daily) appears similarly safe and effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    shares similar pathogenetic mechanisms to those identified in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    failure, with acquisition of secondary mutations after an extended initial response to the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h4\">",
"     Side effects and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    can cause fatigue, nausea, vomiting, anemia, neutropenia, diarrhea, abdominal pain, mucositis, anorexia, hypothyroidism, and discoloration of skin and hair. Other less common toxicities include bleeding, fever, hypertension, hand-foot skin reaction, myelosuppression, proteinuria and other forms of renal toxicity, elevation in serum amylase and lipase, and reduced left ventricular ejection",
"    <span class=\"nowrap\">",
"     fraction/clinical",
"    </span>",
"    heart failure. Most sunitinib-related toxicities can be managed symptomatically or with temporary withdrawal or dose reduction. In severe cases, the drug may need to be discontinued.",
"   </p>",
"   <p>",
"    The following represents a brief synopsis of the most common toxicities seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal toxicity &ndash; Small molecule TKIs that target the VEGFR are associated with proteinuria, which is rarely nephrotic range (&gt;3.5",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours), and even more rarely, associated with the nephrotic syndrome. Hypertension frequently accompanies proteinuria. The factors associated with both the occurrence and the severity of proteinuria in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      are incompletely characterized.",
"      <br/>",
"      <br/>",
"      There are no published guidelines for managing albuminuria during sunitinib treatment; however, good clinical practice dictates obtaining a baseline urinalysis with periodic assessment of proteinuria. Treatment interruption is appropriate management for patients who develop moderate to severe proteinuria (&ge;3",
"      <span class=\"nowrap\">",
"       g/24",
"      </span>",
"      hours). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651225341#H1651225341\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Proteinuria/nephrotic syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematologic toxicity &ndash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       Sunitinib",
"      </a>",
"      may cause myelosuppression. Sunitinib should be held if the absolute neutrophil count is &le;1000",
"      <span class=\"nowrap\">",
"       cells/mm3.",
"      </span>",
"      Recurrent episodes of grade 3 or 4 neutropenia or thrombocytopenia should prompt dose reduction to 37.5 or 25 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/46\">",
"       46",
"      </a>",
"      ]. Anemia, if acute, should prompt interruption of sunitinib and a search for a source of bleeding or evidence for hemolysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229258#H1651229258\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Myelosuppression'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Sunitinib has been associated with microangiopathic hemolysis in rare reports, sometimes in association with a thrombotic thrombocytopenia",
"      <span class=\"nowrap\">",
"       purpura/hemolytic",
"      </span>",
"      uremic syndrome",
"      <span class=\"nowrap\">",
"       (TTP/HUS)-type",
"      </span>",
"      picture. Patients present with hemolysis with or without a thrombotic angiopathy; hypertension is present in most cases. In addition to withdrawal of sunitinib, control of hypertension and plasmapheresis constitute recognized therapeutic interventions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651228686#H1651228686\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Microangiopathic hemolysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism &ndash; Hypothyroidism is a frequent complication of prolonged",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      therapy. In one series, 15 of 42 euthyroid patients with intact thyroid glands (36 percent) became hypothyroid (as defined as a persistently elevated level of thyroid stimulating hormone [TSH]) while receiving sunitinib for advanced GIST [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/78\">",
"       78",
"      </a>",
"      ]. The risk increased with longer duration of therapy (18, 29, and 90 percent in patients treated for 36, 52, and 96 weeks, respectively). The mean time to development of hypothyroidism was 50 weeks. Because of the high prevalence of hypothyroidism, regular surveillance of TSH levels is warranted during sunitinib therapy. We and others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/79\">",
"       79",
"      </a>",
"      ] suggest that thyroid function be evaluated at baseline and monitored at monthly intervals. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651229244#H1651229244\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Thyroid dysfunction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=see_link\">",
"       \"Treatment of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension and cardiac toxicity &ndash; Patients should be closely monitored for hypertension and evidence of cardiac dysfunction while receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21639449#H21639449\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Hypertension'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link&amp;anchor=H21640522#H21640522\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\", section on 'Left ventricular dysfunction and myocardial ischemia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The frequency of these events in patients treated with sunitinib for GIST can be illustrated by the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a study of 75 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      -resistant GISTs, 47 percent developed hypertension (defined as a blood pressure",
"      <span class=\"nowrap\">",
"       &gt;150/100",
"      </span>",
"      mmHg) during therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/80\">",
"       80",
"      </a>",
"      ]. In addition, 10 of 36 patients (28 percent) who were serially assessed had a &ge;10 percent decline in left ventricular ejection fraction during therapy, and clinical heart failure developed in six (8 percent). Heart failure and decreased LVEF generally resolved with medical management and withdrawal of sunitinib.",
"     </li>",
"     <li>",
"      Somewhat lower rates of treatment-related hypertension (20 percent, any grade), decreased ejection fraction (8 percent), and left ventricular dysfunction (2 percent) were reported in the longitudinal report of the phase III trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      versus placebo discussed above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GI bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bowel perforation &ndash; Patients who are treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      for advanced GIST can develop gastrointestinal bleeding or a bowel perforation. In one series, emergency surgery for hemorrhage, tumor perforation, or abscess was required in 4 of 43 patients during second-line therapy with sunitinib [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/62\">",
"       62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227378#H1651227378\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Bleeding'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227451#H1651227451\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intestinal perforation/fistula formation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potential for delayed wound healing &ndash; Impaired wound healing (and reopening of previously healed wounds) has been observed following treatment with all TKIs that target VEGF, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/81\">",
"       81",
"      </a>",
"      ]. However, at least some data support the view that wound healing complications are not more common after extensive GIST resections in patients on sunitinib as compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/82\">",
"       82",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because of the potential for wound healing problems, many clinicians suggest interruption of therapy for at least one week before surgery, and not reinitiated until adequate wound healing has occurred. However, given that these tumors can progress quite rapidly off therapy, it is our practice to continue sunitinib until three to four days prior to surgery and to resume the drug at the first postoperative visit. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link&amp;anchor=H1651227429#H1651227429\">",
"       \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Delayed wound healing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355376706\">",
"    <span class=\"h3\">",
"     Regorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     Regorafenib",
"    </a>",
"    (BAY 73-4506) is an orally active TKI that is structurally similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    &nbsp;and targets a variety of kinases including KIT, PDGFR, and vascular endothelial growth factor receptors. Efficacy in refractory patients was shown in a phase II trial of 34 patients who developed resistance to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and sorafenib, in which four patients had a partial response and 22 had stable disease for 16 weeks or longer; the median PFS was 10 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/83\">",
"     83",
"    </a>",
"    ]. Efficacy was confirmed in a later phase III trial in which 199 patients who were refractory to or intolerant of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    were randomly assigned to best supportive care plus either regorafenib (160 mg once daily for three of every four weeks) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/84\">",
"     84",
"    </a>",
"    ]. Regorafenib was associated with significantly better PFS (4.8 versus 0.9 months). Although there was no apparent survival benefit, this finding is explained by the crossover design (85 percent of patients in the placebo group received regorafenib after progression). The most common grade 3 adverse effects were hypertension (23 percent), hand-foot skin reaction (20 percent), and diarrhea (5 percent). Treatment related toxicity with regorafenib is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In February 2013, the FDA approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    for treatment of metastatic or unresectable GIST no longer responsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25772633\">",
"    <span class=\"h3\">",
"     Nilotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    is a more potent second-generation TKI that targets c-KIT and PDGFR; efficacy in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory cases has been shown in several reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Benefit in patients refractory to both imatinib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    is less certain. This issue was addressed in a phase III trial in which 248 patients with advanced GIST following prior imatinib and sunitinib failure were randomly assigned to nilotinib (400 mg twice daily) or best supportive care with or without imatinib or sunitinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/87\">",
"     87",
"    </a>",
"    ]. PFS, the primary endpoint, was significantly longer in the nilotinib group when the analysis was based on local investigator assessment (median 119 versus 70 days), but not when it was based on blinded central radiology review (median 109 versus 111 days).",
"   </p>",
"   <p>",
"    As has been shown with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , prior gastrectomy may result in markedly lower bioavailability of a variety of other TKIs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/88\">",
"     88",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pharmacokinetic variability'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sorafenib and other TKIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on the efficacy of other TKIs (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , motesanib,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , vatalanib) for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    -refractory GISTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/89-96\">",
"     89-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (a TKI that inhibits KIT, VEGFR and PDGFR-beta) was addressed in a multicenter phase II trial involving patients with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    (n=6) or imatinib and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    -refractory (n=32) GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/93\">",
"     93",
"    </a>",
"    ]. In a preliminary report presented at the 2011 ASCO GI Cancers symposium, the disease control rate (defined as the proportion of patients without progression as the best radiologic response) was 68 percent, and median PFS was 5.2 months. The most common grade 3 toxicities were hand-foot syndrome (45 percent) and hypertension (21 percent). Guidelines from the NCCN suggest sorafenib as an option for patients with imatinib and sunitinib-resistant GIST [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1634255\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    dose escalation are both appropriate strategies for imatinib-refractory GIST. Where available,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"     regorafenib",
"    </a>",
"    is a reasonable choice for therapy of imatinib and sunitinib-refractory GISTs. Otherwise,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    is an option. &nbsp;",
"   </p>",
"   <p>",
"    Emerging results from in vitro studies suggest that the choice of salvage therapy in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -refractory GISTs might depend, at least in part, on the specific mutation responsible for the acquisition of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/58/34730/abstract/97\">",
"     97",
"    </a>",
"    ]. However, these data require validation in human subjects before they can be applied to clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of mesenchymal neoplasms affecting the Gl tract are gastrointestinal stromal tumors (GISTs). Approximately 95 percent of these tumors overexpress KIT (which can be identified by immunohistochemical staining), and 85 percent have mutations in the KIT protooncogene that leads to constitutive activation of KIT, a receptor tyrosine kinase (TK). A subset of GISTs that lack KIT mutations have activating mutations in a related receptor TK, platelet-derived growth factor receptor-alpha (PDGFRA). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced unresectable GIST, we recommend an orally active TK inhibitor (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In the absence of a head to head comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      , we recommend initial treatment with imatinib 400 mg daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Treatment is associated with dramatic and sustained responses in the majority of patients. Overall, 80 percent of patients with overt metastatic disease experience an objective response or disease stability, and the median progression-free survival is 20 to 26 months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Efficacy of imatinib'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Because imatinib is effective in some GIST tumors that are characterized by alterations in the PDGF pathway and not KIT mutations, patients with advanced spindle cell tumors of the GI tract that appear histologically compatible with a diagnosis of GIST should not be denied a trial of imatinib, even if they are immunohistochemically KIT-negative. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Influence of mutations on response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal means of response assessment in patients receiving TK inhibitors (TKIs) is unclear. Radiographic response is often indicated by an early decrease in tumor density on contrast-enhanced CT scan, followed by slow tumor regression. This pattern of response is not well suited to the use of standard response criteria. Because of this, TKIs should be continued indefinitely in the absence of overt radiographic progression. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessing response to therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Although PET scans appear to identify a greater number of responses and at an earlier time than CT, PET is not routinely indicated for response assessment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'PET scanning'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, one clinical scenario where baseline and follow-up PET scan might prove useful is for a patient with a borderline resectable GIST or a potentially resectable tumor that requires extensive organ disruption who is being treated with initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      . Early assessment of treatment response provides the opportunity to shift to an alternative therapy (eg, resection or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ) if imatinib is ineffective. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=see_link&amp;anchor=H8#H8\">",
"       \"Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors\", section on 'Neoadjuvant therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The role of surgery in patients with locally unresectable, nonmetastatic GISTs and those with potentially resectable metastatic disease who respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      is evolving. This approach has little to offer patients with extensive disease progression while receiving imatinib. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=see_link&amp;anchor=H15#H15\">",
"       \"Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract\", section on 'Role of surgery in patients with metastatic disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      does not appear to benefit non-GIST GI mesenchymal tumors, which are treated similarly to other advanced soft tissue sarcomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44680?source=see_link\">",
"       \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who are intolerant of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      or become refractory to treatment, we suggest a trial of the multitargeted TKI",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Thyroid function should be evaluated at baseline and monitored at frequent intervals during therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management of refractory or intolerant patients'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      An alternative approach, increasing the dose of imatinib to 800 mg daily, could be tried in patients who have clearly progressive disease while receiving 400 mg daily doses and who are tolerating the drug reasonably well. However, this approach is unlikely to benefit patients who progress rapidly (within two months) after starting therapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Dose escalation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      -refractory GIST, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32006?source=see_link\">",
"       regorafenib",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      or another TKI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).&nbsp;(See",
"      <a class=\"local\" href=\"#H19\">",
"       'Sorafenib and other TKIs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/1\">",
"      Rubin BP, Fletcher JA, Fletcher CD. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors. Int J Surg Pathol 2000; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/2\">",
"      Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995; 9:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/3\">",
"      Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/4\">",
"      Edmonson JH, Marks RS, Buckner JC, Mahoney MR. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002; 20:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/5\">",
"      Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/6\">",
"      Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/7\">",
"      van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/8\">",
"      Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/9\">",
"      van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38 Suppl 5:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/10\">",
"      Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/11\">",
"      Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626.",
"     </a>",
"    </li>",
"    <li>",
"     von Mehren M, Heinrich MC, Joensuu H, et al. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). (abstract 10016). J Clin oncol 2011; 29:609s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=82574 (Accessed on July 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/13\">",
"      Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/14\">",
"      Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23:5795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/15\">",
"      Rutkowski P, Nowecki ZI, Debiec-Rychter M, et al. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol 2007; 133:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/16\">",
"      Armbrust T, Sobotta M, Gunawan B, et al. Does imatinib turn recurrent and/or metastasized gastrointestinal stromal tumors into a chronic disease? - single center experience. Eur J Gastroenterol Hepatol 2009; 21:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/17\">",
"      Kristensen CA, Eigtved A, Bjerregard B, et al. FDG-PET versus spiral CT for evaluation of STI571 treatment of gastrointestinal stromal tumors (abstract). Proc Am Soc Clin Oncol 2003; 22:824a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/18\">",
"      Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/19\">",
"      Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/20\">",
"      Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist 2008; 13 Suppl 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/21\">",
"      Van den Abbeele AD, Gatsonis C, de Vries DJ, et al. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012; 53:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/22\">",
"      Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47:1059.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/24\">",
"      Bechtold RE, Chen MY, Stanton CA, et al. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec. Abdom Imaging 2003; 28:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/25\">",
"      Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 2006; 79:e40.",
"     </a>",
"    </li>",
"    <li>",
"     LeCesne A, van Glabbeke M, Verweij J, et al. Is stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate included in the intergroup EORTC/ISG/AGITG trial? (abstract). J Clin Oncol 2006; 24:522s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/27\">",
"      Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol 2009; 27:3969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/28\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/29\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/30\">",
"      Shankar S, vanSonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005; 235:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/31\">",
"      Dileo P, Randhawa R, Vansonnenberg E, et al. Safety and efficacy of percutaneous radio-frequency ablation in patients with metastatic gastrointestinal stromal tumors (GIST) with clonal evolution of lesions refractory to imatinib mesylate (abstract). Proc Am Soc Clin Oncol 2004; 22:820a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/32\">",
"      Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/33\">",
"      Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/34\">",
"      Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/35\">",
"      Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol 2009; 27:3141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/36\">",
"      Yoo C, Ryu MH, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol 2010; 28:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/37\">",
"      Eechoute K, Sparreboom A, Burger H, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2011; 17:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/38\">",
"      Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/39\">",
"      Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012; 18:5780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/40\">",
"      Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/41\">",
"      Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/42\">",
"      Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005; 23:5357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/43\">",
"      Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26:5360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/44\">",
"      Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42:1093.",
"     </a>",
"    </li>",
"    <li>",
"     Van Glabbeke MM, Owzar K, Rankin C, et al. Comparison of two doses of imatinib in the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1,640 paitnets (abstract). J Clin Oncol 2007; 25:546s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/46\">",
"      Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5 Suppl 2:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/47\">",
"      Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/48\">",
"      Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/49\">",
"      Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/50\">",
"      Cassier PA, Fumagalli E, Rutkowski P, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res 2012; 18:4458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/51\">",
"      Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/52\">",
"      Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/53\">",
"      Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/54\">",
"      Van Glabbeke M, Verweij J, Casali PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006; 42:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/55\">",
"      Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.",
"     </a>",
"    </li>",
"    <li>",
"     Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:628; author reply 628-9.",
"    </li>",
"    <li>",
"     Owen S, Hatfield A, Letvak L. Imatinib and altered bone and mineral metabolism. N Engl J Med 2006; 355:627; author reply 628-9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/58\">",
"      Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006; 91:ECR27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/59\">",
"      Kerkel&auml; R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/60\">",
"      Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43:974.",
"     </a>",
"    </li>",
"    <li>",
"     Khakoo AY, Steinert DM, Patel SR, et al. Rare incidence of congestive heart failure (CHF) in gastrointestinal stromal tumor (GIST) and other sarcoma patients receiving imatinib mesylate (IM) therapy (abstract). J Clin Oncol 2007; 25:551s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/62\">",
"      Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 2009; 10:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/63\">",
"      Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/64\">",
"      Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/65\">",
"      Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64:5913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/66\">",
"      Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/67\">",
"      Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/68\">",
"      Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24:4764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/69\">",
"      Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/70\">",
"      Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009; 15:5902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/71\">",
"      Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26:5352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/72\">",
"      Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/73\">",
"      Rutkowski P, Bylina E, Klimczak A, et al. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer 2012; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/74\">",
"      Demetri GD, Garrett CR, Sch&ouml;ffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012; 18:3170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/75\">",
"      Prior JO, Montemurro M, Orcurto MV, et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009; 27:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/76\">",
"      George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009; 45:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/77\">",
"      Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009; 15:6862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/78\">",
"      Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/79\">",
"      Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008; 99:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/80\">",
"      Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370:2011.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm224050.htm.",
"    </li>",
"    <li>",
"     Raut CP. Morgan JA, Quigley MT, et al. Perioperative sunitinib dosing around extensive resections of imatinib-resistant metastatic gastrointestinal stromal tumors (abstract 10044). J clin oncol 2007; 25:555s. Abstract available online at file://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=47&amp;abstractID=36307 (Accessed on July 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/83\">",
"      George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012; 30:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/84\">",
"      Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/85\">",
"      Montemurro M, Sch&ouml;ffski P, Reichardt P, et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009; 45:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/86\">",
"      Sawaki A, Nishida T, Doi T, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer 2011; 117:4633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/87\">",
"      Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012; 23:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/88\">",
"      Kim KP, Ryu MH, Yoo C, et al. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother Pharmacol 2011; 68:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/89\">",
"      Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14:5749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/90\">",
"      Benjamin RS, Sch&ouml;ffski P, Hartmann JT, et al. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2011; 68:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/91\">",
"      Joensuu H, De Braud F, Grignagni G, et al. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 2011; 104:1686.",
"     </a>",
"    </li>",
"    <li>",
"     Trent JC, et al. A phase II study of dasatanib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST) (Abstract 10006). J Clin Oncol 2011; 29:604s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=79120 (Accessed on July 19, 2011).",
"    </li>",
"    <li>",
"     Campbell NP, Wroblewski K, Maki RG, et al. Final results of a University of Chicago phase II consortium trial of sorafenib (SOR) in patients (pts) with imatinib (IM)- and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST) (abstract). Data presented at the 2011 ASCO GI Cancers Symposium, January 20-22, San Francisco, CA. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=103&amp;abstractID=70751 (Accessed on March 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/94\">",
"      Park SH, Ryu MH, Ryoo BY, et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs 2012; 30:2377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/95\">",
"      Italiano A, Cioffi A, Coco P, et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 2012; 19:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/96\">",
"      Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer 2013; 49:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/58/34730/abstract/97\">",
"      Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:4874.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7725 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34730=[""].join("\n");
var outline_f33_58_34730=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY OF IMATINIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Assessing response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - PET scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Conventional CT scans",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - RECIST versus CHOI criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Impact of dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pharmacokinetic variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Influence of mutations on response to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - PDGFRA mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Side effects and their management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Non-GIST soft tissue sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ROLE OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT OF REFRACTORY OR INTOLERANT PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dose escalation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25772305\">",
"      Alternative treatment strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Side effects and management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355376706\">",
"      - Regorafenib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25772633\">",
"      - Nilotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sorafenib and other TKIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1634255\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7725\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7725|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/44/20172\" title=\"table 1\">",
"      Imatinib Rx advanced GIST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 2\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/34/33321?source=related_link\">",
"      Adjuvant and neoadjuvant imatinib for gastrointestinal stromal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13098?source=related_link\">",
"      Dermatofibrosarcoma protuberans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35386?source=related_link\">",
"      Epidemiology, classification, clinical presentation, prognostic features, and diagnostic work-up of gastrointestinal mesenchymal neoplasms including GIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34602?source=related_link\">",
"      Head and neck sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34938?source=related_link\">",
"      Local treatment for gastrointestinal stromal tumors, leiomyomas, and leiomyosarcomas of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_58_34731="Contraindications to aerobic exercise in pregnancy";
var content_f33_58_34731=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to aerobic exercise in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Significant cardiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restrictive lung disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical incompetence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple gestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placental abruption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Placenta previa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ruptured fetal membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclampsia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unevaluated arrhythmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poorly controlled diabetes, hypertension, seizure disorder, or thyroid disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extreme obesity or underweightedness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sedentary lifestyle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal growth restriction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heavy smoking",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: ACOG Committee opinion. Number 267, January 2002 Obstet Gynecol 2002; 99:171.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34731=[""].join("\n");
var outline_f33_58_34731=null;
var title_f33_58_34732="Antibio skin test conc";
var content_f33_58_34732=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonirritating concentrations for skin testing with common antibiotics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antimicrobial drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Full-strength concentration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Nonirritating concentration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefotaxime",
"      </td>",
"      <td>",
"       100 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefuroxime",
"      </td>",
"      <td>",
"       100 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefazolin",
"      </td>",
"      <td>",
"       330 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ceftazidime",
"      </td>",
"      <td>",
"       100 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ceftriaxone",
"      </td>",
"      <td>",
"       100 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tobramycin",
"      </td>",
"      <td>",
"       80 mg/2 mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ticarcillin",
"      </td>",
"      <td>",
"       200 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clindamycin",
"      </td>",
"      <td>",
"       150 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gentamicin",
"      </td>",
"      <td>",
"       40 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -1",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cotrimoxazole",
"      </td>",
"      <td>",
"       80 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -2",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Levofloxacin",
"      </td>",
"      <td>",
"       25 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -3",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Erythromycin",
"      </td>",
"      <td>",
"       50 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -3",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Azithromycin",
"      </td>",
"      <td>",
"       100 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -4",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nafcillin",
"      </td>",
"      <td>",
"       250 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -4",
"       </sup>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       50 mg/mL",
"      </td>",
"      <td>",
"       10",
"       <sup>",
"        -4",
"       </sup>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Nonirritating concentrations are expressed as dilutions from the full-strength intravenous preparation",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Empedrad, R, Darter, A, Earl, H, Gruchalla, R. Letters to the Editor. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2009; 112:629. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34732=[""].join("\n");
var outline_f33_58_34732=null;
var title_f33_58_34733="Contents: Renal pathophysiology";
var content_f33_58_34733=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Renal pathophysiology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Renal pathophysiology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/44/11970\">",
"           Mini-case session #1: Water and sodium balance: Part A",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/49/32529\">",
"           Mini-case session #2: Water and sodium balance: Part B",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/1/44049\">",
"           Mini-case session #3: Metabolic alkalosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/53/8018\">",
"           Mini-case session #4: Metabolic acidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/19/22834\">",
"           Mini-case session #5: Potassium disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/24/30082\">",
"           Mini-case session #6: Acute renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/4/25665\">",
"           Mini-case session #7: Review",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/4/11330\">",
"           Renal pathology test: Case presentations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/63/2035\">",
"           Renal pathology test: Pattern recognition",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-CEFD44C522-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f33_58_34733=[""].join("\n");
var outline_f33_58_34733=null;
var title_f33_58_34734="Mucinous cyst";
var content_f33_58_34734=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucinous cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 255px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The dorsum of the hand is inspected for the presence of a cyst, which, in this case, is appreciated distally near the nail bed. The size, shape, and compressibility of the cyst are determined by physical measurement and palpation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34734=[""].join("\n");
var outline_f33_58_34734=null;
var title_f33_58_34735="Ampullary carcinoma EUS";
var content_f33_58_34735=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ampullary carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJATgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5yjwBk8ipsmdTsOBVcnapp1vIQvy9aAGOzRSYfpVqKRrgqo+6KSS2eYbyM1YsraRFwy4B70AW/NtbOLCqGl71WillaQ/KeTxUqaeiOZJXzurStYVtEMzOT6A0ALY243hrlyqn+Gn6lPCF2QRMfeo1FxOxMQ+90LdqsxCOI7Zpw0g6jFAGKbl0j5+XBq/HdNcoI4jtz61WvbZZbgfOdhOcCrdpBF9oUoG2J6UAStbYjAdxToFCcIN1PnVZG+62M0RtscKqstAEibkQif7uc81LG5aRFt4/lqSSBWUFmLFuxqS03W+SSCB6UAXtv7vYOG71Ql0+SJiVCkt3NWPNEilo9wb3qneu4IZ25+tADG06fcC+3j0p84QIEfg56ipUlkdVUsAKhvsRAMXHX0oASKNArFXPHrVUzwlilw+G6AirtrI8yYXBX6U290+MKZHTOOaAKcVmsblmcSIelTMqLNGiAYPWq8cLu6hGwo7VaNs5uAzHG0UAMuosMAyqVNOght3gdSrB16fNU0bM8wE0Z2jpzVq4t90ZaFRt9aAMZIZ0jkkV8gdFqS0lu7lgjsQuKsrHsRh0Jot50g4cc9AaAKF5pxEmc5NUpoPKGZQWTOMVtymVSXdgVPSoIHheXD847GgCvDoz+R5mMxsMgelU5V+zAZBXnGa6m3vRGhAAKnjntVXUmtHiIliJxySOlAHOS3SJ81udx7mqjTmZy2eanubeGPJhzt64rMLpnGSKAHXDluDyar1NcjA+TnioaACkVQ77elLTGba2eaAL8cMtm6zR/Mo5Nagvo7pOVwfesizvWTIfJQ9c0k0ib90BOPSgC7JprTsTAAW7CiqtvfzW8gdXx60UAVCMjFWrKzdzk8J61Wq7aX3lgJIMgdKANuCIW8Cs6/K3GTSO3nSCK3G4+oqnNc3GqusUY8uIdxWhHcQ6UhjgIZ8csetAFxLC3soA9yS856p/dqq+wRmSZSEHQVQfV5ZpD/ER1Jps1zcXK/Kp2j8qAL8mppKipAQg6e4otNJ8+4EilnyeWqrpwTzd0qqqjrWlLqTjCWvCe1AGtNbadbRAbt8oHSsq3kihncj7rHpUjQm5iDtuD1DdWUafNE5L0ATrDcXM26DaEBzzUrr8+A8Zb0zVS1guo0LNLhT1FTQQxrL5gALj0oAuJbOFyWLE9hUJMlu53xNVsThCGQ4cdqlS6nm+aVFVR60AUhPyN3Q9sU6eO3kAB4apZJ43mBVARU9wiEgbMHFAFdI0hZAihhSzSoJFEkIYA9MVZggkhwcb93r2ouW8u4VZEB70ARmYl1WOERp1JqG6uRIxjUbgeDir0kjSoVEeEx1qBIoomUqnXuaAM+O3mD5gj3AcGpL12CkN8p9atTI6yhreTaT1FRSW81zMUIAzQBXaDaEkaRsGripIFG2UbD2pL3TrpIVO3OPSo45TjDfKR1BoAfPZOy7kZfxNUvsrvJscrg+laEIWUkZzVa6SXg26/KnJoAxb7zoZvL5KDue1JaptZnClgR1FWZUN07B9xHfbVqzRLZdsPzE/wkdKAITLHs2nKnAqPzJVRlmAMRrUZEIKyKmcVUgRrRZAdr7ugagDFvkiCloW3A9RWLeJCUDB8EVtSXCyXMgRcEdVrIu41kkJkQKvYCgCtvyBjmm0bQM+3Sg8DNABT4xGxw5waFQsuR0piwl235+72oAuG3jChg2R6VTYESsQMLV6MAKPftUc6bwQg5WgCqeeDRTQ2WwAaKAHUoweG6GkoHFAGlDfLaWu2A5c+tUXlaZslsEnmmcZJxTYxyTQBfso2eY+XyO5NaF7K4Cw2xG7HNZqXXkx7U6nrU2nr5lxuL84oAsRqyFBPyW9KvBQrRpEDvY0XMXkRrIRn0NS216nmhwAXA4+tAGvZ2MksR3ylSO1SQQLCrecuTng5rPtpJ55GM8gVs8Ba21Kx2xMhBIoAilt0nh3Rg4HrVWAxxthUJar0M5kKiJDtPUCn3DAfu0hbf67aAKsUaNchm4b0qy4VJCpOd3arEWnEWZnkwrdgT1qjDgyOzNnFAEsNnCHaQ8egpOWnJVScDjNRTO0rgqcY7VcgcyLjYVIGKAIBPcMSCAqr0qW3snvIS4c+b6Go4UbzXQ5OasJI8LtGpKkigBkwltYysoycYGKRSZLdflx61NEW3hXO9j0zUos55ZANpCn0oAy5I1Egw2PStLS5ktrkfaArg9Kr3mnvC4MvyYPGamt7a3edCZRnrQBq3d3DcQZWN4wPSuYnjN2ztED8p5NdedHiukDR3QAH8Oao32kXtvE3lxrJET1WgDmYI51G5YyfXFFxPNbsNoO1vvAip2e5t5DG25B7ilm/egJJywGc0AVkkggxKDhm6r61Xndnl8xUKZ75q3KiSooAGEPPvU10I5IAsQ5A6CgDLaIs+8ynj2pkuZWDBsbaHcplWO0e9RqvnAqh60AZmqIEPmW2PNPU1kSzPJ/rRjtxV7U7aWFjhjx1rOUFuTQAuFxSS7NtKUOOAasw2rSrkISO/tQBRO4xr5XKk81bCFQGjGSByKlkjKL5ar93qaismkhMhGGFAERY71c5G7rntU8UsSTZbDbhtqe3ZbyNopI9voRVO8s/J+VCcg5zQBYvVhEZMaY7ZorPDu8R3HgHpRQAyiiigBc0lFFADV+9mtjSmRGLSY6cVkjik8zBPJFAGzLPJPMVeTCdqkhWOJsRksw5zWLE5ZgWfCDrmtmzl85xFEmPQ+tAGxpULz3AlmkwvpmtdrB9ykuSvcUmnWkcEKvcD5xyBU0+oO8wWJPkoAlgXymGOOeK1byJbWyE7MCTzwaxissh7havJaRTvHHNO+MdD0oAd5iPBHGjl1PPzdqrz26h8RD2JFWJ7i0tv3cZ+YcZqSxZngIEZIduCRQBVliS1CAjLHvVyRFAV0646VbOklWWSVsD0JrUiOmWkHmzYeQcYoA59bSeXBtlJY+lXF0S6eIu6jf71bl8Q28K/6Bb7HPtVOTV7x0Lu+COcCgCzp+j3AfzdqAr/eFaaJflD5flIw6HaK5FdfuHf5piqg9PWnXXiS2lwiXDZHWgDXvtOvr2X/SY9+P4hWY+ivHOcRSCq1p4hZnIiuHIBq63iC6P+rcEj1oAz7uKSKURiaSL3q9YC9jT9zek/71WrbW4DHjUbbzAer+lWRc6TOv7n5T65oAZDcl08vVFSYnjIXmql/Y2rMfswwpFaKac0oMltLE/tmsm8tL63ugHAjGM7j0NAGd/Zs24sFLIOtU7g+ScFShrVn1ZYIWjl++eAcdayZpo51JJBNAGTdKsjffyfes2W7ktyUQEHsauXTxJMWyc9qijXz3+fAPY0ANtJV1C3KMD5oPOe9RX9gIe2MVGyNYSllkBJPArfW4trzTlSdT51AHPQRfuzzVi3RLYHbIzFu1R3BEFz5Y4U08QSGRZF+71oAcIGEjSEHaxHFV2hEExkAzEeorTEhkU569MVl3bvFLsCHB5zQBHKxik3R8BqpXE7hyG6VIXdzl2zTliEwYH0oAqiIvCxU8minxQukgP8OaKAK9FTXIWMlQvPrUcUTHr36UANoqUWbg7S24noKkmsnQDby1AFak2g9RU0kDwjdJ3qLg9OlADHGBxWlpk3klZCfu9KoEZ69KkiVmBI6JzigDsoNUkuYgzLgjituw8hoflO4nr7GvPrfUpECxleCcZFdJobbbkgsSp6gUAdFG7xPiIj6mrmyeYDyFEkvcjoKoRzgnCBVQfeDdTUourwMUtVVLfsRQA3ZHDc7L1V3dauvq9uYzFbptKDaDis7UI7UtCXmZrg9amtrXyySwyMZ20ASC9uHCjzDIx4Oe1WrrZHCC5y2M4zWdIsj2rPGm054IqCK2kWESyszN/doArT6nKku4L8oqP7e077ncqnt3ro7PQ/tib/KJGOc1rJ4XtVgA+VcetAHHW0Uc8m5WbkdBQtokYZvIGB1OM12Nt4fVM+VPGAPTFS3OkSSIY4pY+R3xQByf2SHylMCAFhkkCmiyfqCc1v3Wk3trH+6CHjHArIvJLm3MQmBy3oKAMh3vIpSsoBXsBSpJCZl8zcv0qzLdhbhdyg59auGK0uYeFUSUAVkvXtrgNZzkD+7mugt/EUscITUo1khPG7HNcZdaUUlMiMQT0ANX4ZpYIB9oTenTJ7UAbWsR6ZqEIaAqkg+6PWuRuFaM+VnBHcVPqEEkpD2smSe3pVOJpmPlXLFf9qgCC4i+Q7hk5pkLiORQccetabxxpEVc5B/iqpPZRpEjI+/NAC6nFDewoeFdfSqNuZYZuPmBFWrGCR3cHkjoKtJbTxnJjyaAIZY7aeISsP3oqCK4YJsK4UcZxW1Z2X2qIhUxJnrTZtMNsjC4bn6ZoAzLQJcOyjggZFUL24l+0eWY+AMZxWmsKwyb4umai1SISRiVGIYcHAoAxjEu30Y9KbbZLmM8ECr1rbpuUTMST0J7VN5cMMj7V3MB96gDLuAVcDPFFWmZJVJKYIooAy5kZ23IM5q3DbOLYM4+b0pbHYqqp+Zq1FYywupj27TQBUtLRYbd7qXcWH3RTrEPOwcqcHmrhXzgsZ4jHUVt6TaKSI4I8g0Ac9qGnSXy4iXGKw7zT57UfMMgda9NubM2uFxgIMsa43XLvzZjGigoOpoA5gtkfJ1oDsOASM8Gr72apHuQEuau2mkOYRKynd6UAVbOGOKISSZY9qki1JrYv5asJG6E0+6srhYt7gqAelZckv7/ADk5XtQB0UF8beBJZX82Zj90V0Flvlj8+W52KekQPNeepIyziRW25rotIuo922Qn65oA6u7niSSLyYdzerVbhmncliq+4zWOuoJ5sSqpYetb2laU97dec+Vi6nmgCXT7G7vpPKhUrETkt2Fal8NM0ODfdzrJIOcZqDXvEtrolm9rZ8Ooxkd68rvJLjUpWdySGOcsaAO3uvHwWORLJF+bpiubn8T6pc7z84z0wazI4bO3w0rguvao5NTUMRAqqRQBdj1XWHhYlpASaSLVNYjOVkkz7mse51i4Y7Y92fao11K9LAYYH6UAdlaeKNViA8/cwHUGugs/E0F7t+0w7ccDIrzB9Uu1OOT+FTR6xMuNybqAPU7rSrS/UPZviU81iXFhLYTbpwwC9x0rC0vxQkU6ko4P1rt7LWIdVt/KZVct19qAMcyi4dSnOeMVqXWmytaYETZxnPaoNQ042W2S1U+SOcjrmtPw9rjrKlrfgFXPEh9KAOUjje0nxMcqT2puqWgught25zxzXZ+L9FLW7zWa71PIYV5/aTyWsmyQNlTzmgCe18tWFndg7pBwfQ1cbT/s0KrJy3UH2qneyxSwmaI/OvetuJRqOhRuZCsyjt1NAFXTrZEk35rRneJ5ljReP4j71mQx3Aiy2do71oWRjktpVPD560AWtPSG3n2uR69asa15N5tEUfKrz71y9wJorrzA7HHQVe/tCQhG4XAwcd6AMefhnjxtZegqJJDGnkzhfmPGa0bmBZiJgeSeaqapAqNC4z8p5oAq3ChEYsASnQCn+UraaZ0GWX5mHtVdZBJczEk7cgEelWRDIrfuSWgYfNQBm3pEYjkA/cuMnFFJIjJ5gI3RDse1FAFDRoZMNLKOAcitO21DJdGUDcaqecRYIsZAJxmqU8pXAXlqAOhtD5t2EXv3rr7OBrGLeCASM5rkfDUbyt5pXhRzVnX9SmUqiyYXpQBJ4i1aaYvDGwDN1bNc3E8dxLtU8rwT60TvvgYK+Zm65plnb+SVYKSSefrQB0eiWHnzjeo+XoDXTpZokyggFRywFV7K2e009Z5FwzdBWtE4t7Ka5mwS6YANAHB+KLlJLl4YTwK5RrSQ7n2k+9dBMhuLiaQrg5qezTMTAqCvegDkUG59pBzmtiCNhEQqEH1rTk06AHzCvuKdD1GQB7UAanhy3kmKB4+RXWa1qf8AZukhYztcjG0CqegER4Ow4wOQKzPFNyHlZpB8q8AUAc3euJS0t5IDnnnvWPLqDTkxwrt7ZFRXUj3k2Gb5M8Yrc0HRhPKuFLe9AGPb6a7vliSW6mtW10He+BG7e4Fdoum2dmoeTaWHaq76gzsVgAiUdwOtAGRB4dkVQRFGvux5q0nhwkZaeBPqaS4vgJDyzGod7TDdtfHoaAHyeF5Hzsntnz2Bqhc+FryA8wBwe6Nmr0ZlJAQN9CMVbtru4gfaJHjPvzQBxd7odzE5Kllb+6wx+tJo97c6Xc5lVgmecGvQHuorldl2ok/2h1rN1Tw/HNCZLbDJnOKAOn8NarDqNuFfDxkYx6VR1qxaOR1bmHGUZeCvtXJaS1xo+oAAMqE9K9OiaLUNPAYA55NAGLoHijyo10+7JIPyoWFZPiu3WO8Z41DI3JIHapNY0yKKZZlXDRniqN5cM8ezcT9aAMuQxphUPD9q1PDkzrcG2IzvOAPSsp7djcxsegqyxlt7yOeDjaQaAOnmingm+zzrhSMg1lOklndEZ3o/OR2rY1WaS6gt51fI2gEiq8YSS4RGI24oAyrwytEZ+dqtjHrTHjeMqGzyMmti5hUW0kWQCWyKqTHdc4cfuwOMUAVbW4QExnk0t66oqJIMljnp0FV2eFLrCAhqsLJvkYyKG42qPegCoIoN8wjHDDJNR6dcSRK8TJkE8VDdGeAlcDcT2qW3Mgk3YHTp70AUZlaCd0kUsjHP0orUMYkkEUwAZqKAOE86XhSeKfC+2QE81HQOTQB0+nawLSJ14BI6etZtzJLcyM8pIBORWfvYyjC5rpNL02bULclVOVoAzbGyeSYlSWzXXaJpUrSrvj4HYir3hfRmjLlk3OtdAk1xBOMQhQKAI9RLLFCJVOE4A9ap6gN9qzE4CrnbVvVbyR4h5wVSDxWLqdxILZi2NpHBFAGTHGHR8gBiMgVn6V8ryxScNnpWraSAgOwJGMcdqNO02OW+lk3EYPegBrxHyx3qpaQeddneNozxWxPaFM7Xz+NQW0Y83IPINAHSwxfYrJmWTOBXnHinUnmnCLyGYjiu/vps2ExXBB/wrzmCHzb97iUZRW2haALnh/QnuJ4kdcsefoK7IyW+mx/Z7YASA/McdKr6VAbOzknZsSy8L7CqCSt5x8wbmJ5NAFzEly5z94ntW9pfhp54w0zeWh7nitHQtLtrS3+3XzbVwCoPesXxd4tit3bDbR0RF6/lQBuRaXodmn77bMy9c1L/AGlomNq2kfy968njn1/XrlvsKuI/QKeKvnwP4odQ7vIAewBoA9IS50e5ztt0HuO1VL7QrW8TNo4ZvQV51d6L4m0ZQQHKdTkGrGieMJ4Jhb3uYH9cdaANK/sDbvsYFTnAOKNMvDYyFHG5G612FpNa67a4lCiQjCmud1/TksmKHgA9T3oAbrGmpf2ZubTqPSmeErqS3uzb3cnHrS6DfyIXtyF8lhwSaq3SPDfE4wScg+ooA3PEUOJUdR+7bnNcjP8ALckE/L1ru9RHn6Cr9WVOa4K9Uk5oAW6Kx7ZT09quNEJLVmXkkVHEEmjjXcMAc5qyizGCQj/VqOoFAF3QyH097NjkdcmoZIfKukXJDL1qnpV1sm+U9627yNZUJBw/XPrQBnXf+kP8rHgVLFtW3BYAlTjNVnnOM7GULwTjrSLLvVEU5BOaAItcthF5N1GDsIwfrUEUmHScrkdq2tZMZ01YeuBnHvWC0rmBdijAGMUAOcb53lVck84qNd0k6ykEBT0ohNxkMoAAHOKnszJKWV0xg5oAr3rn7YshHzdQKKv6pZ7p4GQdeOKKAPNG6U6MZ4pKUcUAa1hagNGZMYJr0jTkgtII1iA+dcnFecWE3nLGJOB04rudKmBl8rrhBigDo7fMEBaH7xPOKm1C7X7JCwXLZwTSaOkUJHJ3sDnPNZuozpE00fflgKAKusOVCtISyk8VQnDTJgnMeOKnnuCbDZJyW6VSMjR28KqCeTmgCG0XZ8mOCafczC0E2Dwe4qKyMk9yyY4zUOpxYkCI3B6k0AWllARGDkkjOKTzCZT5fFNEkcIAcFsL1AqS0SF/3m9+egxQBpnK6eUIPNYlpbxjUUhP8R3GumjIfTzHgH3NUNHs9+s5YZKrQBa1HHmJGOiijw5pH2vW1kfPlJywpdTXE4+tdL4VHlW15KAP9VigDH8b62LaCVQf3EQwgHrXDeDNDuPE2qG61A/6OvzZP8IHNTfEGdhbQIudryc+9dKztovwpurqH5WndIcjqM0AZ/iLx2mlO1j4ct0UgbJJgOciuMfxfr7ys0uq3RY9MHAFYWGSZ3YnJYp164p3PdjmgDq9H+IWu6dJ/pFwb+HusozxXV6rp2m+LPD0mqaXGsVyozKq/wAFeU89ia7r4NXsi+JTYH/j3vIHVlPI6UAN8H6tc2l59inbMkR4r0zWFTVtBFyYwZYhgmvKPEkP2DxqjRHAZsACvV/DrF9EuAeSF5HvQBwEUjQb+CMHgVqarm50+3lX74IGap3S7ZnGOSa0bJY5NNdZTgb+DQBsWkvmeHrsfxKoya4e5UOVUtgmu4giWDQZCM7SRn3rk2Fvh5AfnJOKAKqRGGAoq/8AAqu6dMUtpFmP7vHNQorvZsX6g0xSP9W44PXFACWkUcjM0XAB4rZhlwP3nfgVkafc29vK6MvArYtzHc3CD/lnjigCK6TzIynOM5xVW3g8kMSMbeeauEkagIx0JxSasUSfYeGA5xQBQvbnzbN5e4OKo28rMqZ/iHSppIzMm1GAUnBFS2NutneKZzvyOFFAFi2jBcKTjd0qtfT/AGK42Dknjir1ykanzQCXP3QD0rEDF74NICDznNAF6/uXAh8vOeCeaKrTzBraNQOc9aKAOBNJFG0khyeKmdV2BgMilsZAWI20AWLdZIHDqMrXTaXeOSrYwcVn26D7MTgVb09lSQE42gYoA7nS38zTpGDfvz0NZN3Nu3h1LSAYzUmj3ixo+4jOOKN0jyPLGAxPFAE8llE2mRSq3zAdKq3kMMenxMXO4kjj6U1bp9rpKMAHFV5pFYkdVHagDO0/5JnSOVg5U9aZNGzYX5iy8k1BPkagHThemK6DT7dpcDON/U0AY+55ZAQPl6Gta0iUArkDA4FRSwLDdPD5ny4PamxkwABjknvQBsWcoA2Gr+mDy9UIA5K1z8UpieORj8pNbyKJ3S7tnwVXBFAFPVwUnJPrXQ+EpxLbXUHrHXPasktwiuOh61Z8OXX2K6EhOExhqAOY8fWji0jZRnypMmuh0qNfE/wzvbOB1M8WHEZ6kjuK1fFWki+tGlhwYZByfQ15pot/eeDdb7tbA5JPQ0ActNGY5NkgZXVjuB7N3puDkk9+lerX+jaL4xP23TryK0vH5ZX6MTWFN8LtdVyI5Ld0/hbeMGgDhHzsODg9q9G+D2lsup3Wst8lnaQ9T/E/oKl034bpbMs2u6jHGEO4xoRgj0pfFPimys9MGjeG4cKrZ4HU0AYWqsdT8aL5HzRowOfSvWdJK2mhzSMMhhXA+BvDk/m/bLjPmy8la7LxDcfZdPFjH94H5sUAcxdkNKWHQnNXrUKdNbI+8cD61mmJ3kUKcjvXQWFq0skNui4VTvNAEuoMbXw5HGRy3WuMnVfLbse31rofF145uUtYj8iA/nWGsIlMankjmgB97I8NvbIi53DB9zVdE+zXW9yW3c49K1JNtxIAg4jX8qxJnZ1m3HL8gGgB9uUNy7uuVY9K24RtkjKHYuOhrP0q02WKtMMyE5BrR1E/aYRHEmJBxuFAFWMyrqSqvzgnr6U7XzsuV3feYVE5FrEmDmUnGc03UWMwjkk5cLQAyyhLgAHoc0t0GjYy9SowKueF0+1XKwt/y0zz6VF4kQ2MzxMcqO9AFCzuZ5rtjt+70zVe9MqXbSSYwBTNLu/NlbaTk9KuakhaNy/LYoAyFZrhxsOOelFOsw6RM0ceSKKAOWilxFgjIqzAnlp5gxg+tVAcDpUyTkKARlR2oA2rZ91ixj+ZvarMQH2Nd/yc96qW+DbZg4J7UizyGHbOhIzQBqR3axsAPmJGOK1bKaRU+9gelZdjbQ/fkOM/dFbNtbSSnaflU9DQBVuJmkLBTk96qqzeUQfvk7RVy2tjHfTK3KL3qrfR/KwU4ZTnigCtKhQrvI3Z7V0+ltgIDXJQlmkAlJ69a6fTJYyVAbmgBl4E+2yEckA1TRhIB6+lTXTlb2RgMjBqhsyfMDbc9hQBoTQvPZ7v4V9Kj0jUmtXMRJ2e9JazZBj3HYagvLZEcPGc5oA7KEw3dmBG65AzisaRGiRvlIO79Ko2TvasjxufeumguINQi8tsCXFACaHrixD7LeZMD+tWNZ8NW+oQM8SrNA3zADqKy9Q0pkUFQSR6Uun39zYkBCykepoA5a58JXdnOzWNw8I6+WVNQ/ZfFOMI7uF6Hea9NXxCkkYN3DG7evenRavpKjdJbN+dAHmKaHruonF3dPGO/U11PhvwQkB82RDJJxmR+ldE3inTrdiLW2z6ZGay9T8T3t0uxUMadgoxQBtXt1baPbGK3w0pGOO1cnd3peclwWkfio/9InfcoYt71fs9NOPMn+aQnpQBFpkRTiQHex4rofOXS7F55P8AXMOKgt44omEkwwV7Vka5qHmy7QN4z0oAx5ZzPctJJy0metORPs8DzE/6Q4wgqWC3EjtJJ8qjkUksollWRhhVOAKAIbGcQxO0gPmyct7VlyfPcFYASWNazBBvK8k8Y9KqadthuZZFG4JzQBrbglvAjLhuAas3kotHZQAQFzVKKeS4XzJVxz8oFT3sZkk+Yksy4IoAydhlZWfoDuqaWJp0whCletXPs6xgbs9PSq1yMuFR8UAaHhtEhd2UnzAOD6Vznje7maQoQGPfHpXUaRbvHEW6hh1rivEM0gvZdozxjmgCjozFL5BHnBPeur1l47aNWfktwa5Tw6rtfRl+oOa3vFcwZ8KfkK0AK91FHa+Vb7W3dWorEt3McSxoMKRk0UAc2h3g47U9Yn2biO9Ng+QnPU1fhfzItqjmgC7px2oXU/KB0rcuDHJYKUVc4z0rm4TJFN9nZcKRnNallKFQq5G3HFAE9mWuZF44TtXQWlxI2MrtRetZEAZYg8A+Y9au6Vc7pJIro4XGaALeoLs2zRkbM81Wugssn7tCN4q1fbRYgggpnIqnbSrLypPAoAzo4lWVhIcYq7oqruc78EHvWX9iuri8d1JEQOSDV6ExpOxQ4HQg0AXp3RZWZ2yCMGqVuoaQ+W28dAK0lsllYqxBJGazRGFuSkBKkGgCxbQmOJlaNg2euaEBDFGX8acZiVPmSdOKqz3m1gFOcUAXCnlRncazkvCJeXKYPY0z7aBIRK/FIn2S4k+dj+AoA6nTPEDFfLkw4HQ+tbI+y3qZ3ohPY9a4G4EUBjaFsN27Uxr2SHEjOST2FAHbnSJi5MeCvqDVGTTrxiV2sB6k1i2XiCWIhlmYDoRV5vEMwUPHJuI5waANa00eQIPNkx6jFXF0wKSfmfHGKxovEcokBkweM1ZfxO82WRdgoA3oLKRUyqRp9TVW8uobLcSwab2PFYNxrjSrtBcn2rNmR5XDM5II5GaANC/1ZrkkKcOe9VbQFrgFhv4qs9uIWGcnNWY7iKxA8w9aALs6NtCkgKTzVWVkkmIVTsQZPvSXd8kkSuDkeg61SuZVayZom2ueMUATSyebIBCmCR19qW4t/sohVDksfm96qaak1tama4Y+wrTtlE0DTykED7tAFy1hSCRZfM+U9VPOKsuEe4eTeAifrVY26m2813AXHSqiuJJ4rYMeRlqAHalfMqKwYAE4ArNcskisWLA+lP1q3+d1HRRxVfSAzpiX+EdTQB0dheKtqCoYEA9a8/8AEN04uZA38R6iuta+WGEqi5K1yOsuss++YYTHI9aADwsxkvShOOMhqu6qzNHISckNgVlaLJmciLjH3a2LmJjOqtwBy1AGbLMsUSM3ptxRUV4okmY5/djpRQBjwjzGB7CtOIxhgITk9xWbbko5QVb00f6XkevNAG+FWRkkmTbhcVUjaLJA5wa07+Lzrb936VlP5UKjcGBx6UAaNncyBtoU4FPc72ZwcNjGKoWk5N1GEU7SOtXg0C3C7sl85IFAF2SVGsAhkyyjkUumBYdrZDDPIpNOEc108bKArdMipJIGiuZYoxujI5I7UAdI3khElt1Vt3UVi69ayR75EiUYGcrS280lnDiP5oQO/WpNQ1NWs4/suHZh8wY80AZlleuLcs5w3Tml8xElMjHrzWTevM0W4LtbPAFJAWnjAuGCkdMGgDSvJofJJTkmsKS4KSgg/hU07uP3ahio74rPniIDNu5FAFyecOPnTr3ogJiQ4HWsZ5nkAyxAFXbW8yoV+cUAacd1GzKJe1TNcW6oMLuNU2kicYGM00QSbhsIwaANG3FvLKCcqKtm3VcsjqR2rClE6SbF+73xUDzlGxI8inNAHU29sgj8oyDB+bOasPaIsQ2yD865aG53fxnPSrUNz5LbpnYp6UAdNBAIgCWViaYskUbu8jD1Fc5LM8n/AB6ysSffpUlvK4BWcg460AbT6grt+5TPuaHgR186Qhj6VQiUvCTHxmqxS5BKlzz2oAdJKIZiI+Se1WVkjgjWebkE42+9QRW4CSPKQGA71lIZjMVckxqc4PegDoLWea9uQ0w2wDgLW9ceRaWca459KzPD9mQnmSEndyo9KmvX89tsnAXpQBObmGS0AbjbyBmqtvcjc0rR4PY1Vh2FmD5AFOgnDuYfLI54oAS5ke4ncjJyKGDR2KqwxJ0NJNOtpMDjJ70rz+ehkYbVPIzQAqom0In+sYZ59a5zWYHZyGOWHWtyScJECDhweDWbfriIOXBZuTQBnWSFpofLwGTk1c1C7Z4dqZMmcGq1vGUBZT87UXsqRYjX7x5JoAq6tMoEQiPb5qKozOXuACOCaKAHjEZye/WrkXlW6+YO9UREx96nibemzGcdqAOjsZhNannHpWVqiyicZJK+wqO0vCr+VsNbsUJcowUFQOe9AFLSj+9Xj5QOaU4+0seOtaEdsglZhgAis69iDSboyQBQBaaYwMrCtnSbvdKGf7rVhwuksYHUoKlhlMcwJzgUAdrLarLGXhTeuOVrlmgVbnagCDd0rQbUZUh823bacYxUVvbNdN5jA785JFAEF7bfvB9KxXiAlOa7e509pbXaAcgda5G+gMcuzvQBBnzBt4FZ+oWrlgVNWowUixKcDPWpVEbICGP40AYdxp8zBS67UPeo4rFkkAUkiuiurfdbKqkkP05qnKRbx7QPu8UAZjQvE+SSMDPNT/apUAGeoqvPP5+cdOh712lt4d8NXPgm21i3uNbfU7i8+wLA/lGH7RsRyc4zszJj1oA5u2mlC7nGRnkmrplgndS8YyPyNW5fDOpWlnqsk6qkWmTJb3RV+UkfcFwO/KmshrcfZ0Jl5+tAF8WyyHKRgc9aSW0UD5+QKSJpTEqxycDqau2sDSjJkBoAzmliiwEGKak8Jb93kSerdKW/hCzEYrLJ8uYoTyTQB1+jQSShpJCCg6Yqp4hvYo5ljgHzjrTtCHyhWLBfrS69aRH54uSFoAw7m785DEWIkbArS03To7iVEkmGQMnBrNtLGe4uwqrlT39K6Oxs4dNHmSZaToaAJLSTEjW9rLudTtxmlullhumidgCozk1Ho2mPJfy3aApHy2aTVS5mMhkGGGKAJpJ4kQGQea3qnas5J5ftZeM7R71Xa+/s9DsHmM3f0qa1tnuLYXUj4B5xQBK8YmuJD5nJFQ3k5S1RP7p496illBA2kq3TNRzzR/KHbLUASkpJGGkcDHas69uI3P7tsgcUt7LuACcZ96oy/u12AcnmgC/ayYdGP3cc1W1BQ0rSj7pp0SymNXkBAAyKpSzEzHB4PB9KAIGBEg/nRVmZRJFsi5z1NFAEUrGIgq2c9adavict0BqJxkE+tRxNsUBu3NAG+zIqBgoDEdaW11E2JJZ2dZP0rKN7m32sPm7U+GEXCBS3vQB0AvfNg2xgA8nPrWfFqEwdkniGCcVWnLxwbc/dqxbIJY1yMmgCzbwlpsgkKR2rWgtUaEOXzg81QTMDqpHDCrdtPGhZDwCKALTKJSqIMKK6i1iEdlhVwxGc1g6X5TxFw4ODxW9HfQpBiQZOKAIJ5ZGXYruDjnFZYtY2lPm5Zj6ir3ngS7404NW41Wb5toBoA5jVdNSKAyZz7VgqIwctu+ldf4hgMewZwDXP3EKSqUQhX9aAIY74KANmVXpSz29vqSnyyY2H61QET2smJiXB71orEs9oywNskzwaAOdmszbzMhIPuK6PS/EEdl4XttJ8hjNBqh1FZTyp+SNQuOucx9fQ1guksUxWZ9+D1p52h89FoA9A8SeLtKvdC1q0sNNvY73WLuC8uLiaVSAyFyVUD+D5+O/JzXHNFG0SlhtxwRgjFEIW5YJ5gjXrmp7hYyfl+YDqfWgCO3SIDKMR7VqabIobD/LWWHCj5EIbtQy3DKSTtNABrl4kU5SMZHrWTBG1zPub7o7065hZQdzbiaZZPM0ojU4WgDYt7n7O+yMFnPTNaMMcs8avcDaxbG31qhHA4KrEoMg5rf060mnlVrk7VUcCgCCZ009mdPvHtTbdjcuJXOR3Bp+s2eJQM7hTbeIQQZLj5higC9d6usUBitsLxisK4ljmbMjY9u1KYIcl5JeAelZ1y6rJiIFlJoAnuthQAIuO2KQXbiIW68Cqe6eW7Eaj5e1asemyxkyzYOe1AAtq9xGqIM56t6VQvbVbHCFt7Hgn0rRh1NbOzYEfNzisG9uzcFnJ5PNAC3SRpEGV+fSo7WTeu5lzjjNVpY3KK5yQ3FXYEEcGzu3NAFglZojGHOR2rOuI440Ck/MTUjHyCWUcmqckpZt3cc0ATIUihYDOT0oqBpTL94c0UANL0w4JBpaQ+tAC5BYdMVYtWdXG3rVTJ7VesDiRd/egCUtJLIUZflPWti3SKJAVPOKrhVDOyEGoYy7zfNwKANJrhndTheKsOVwrSoCCe1VIfvAJ81as0RWBXUgkdRQA62tj5Je2cKncGpxMRiMgsx71TWYMowMc4xV4kwBGHNAFgaisQCMnPTinWyXH2rzcv5Z7dqrzKsluJQQWJ6Gnafq6NJ9nDbpB/DQAeKJUa2VzIRIK8/ur6dZSVavQNWsxfR8/K/8AdFef6xYT2krCeNlUnjigDb0nXbeSBYLuBTL0DGrlvZCVmeSQoDyoU1xabjIpBAwa6SydpQvzHgdRQAuo6fsLEPkVTEaNHtJJIrVu4kMXzSHA61m77dBhScmgB1qkTOIxkNWlPFEiBlByOgrPik2SB0jJIokvQWw/yd+aALtuWKl50wvt1qjeXEk7lYhKAOBxS22ozB22Yde2elQ/2vOtwVwgH0oApRs4lEdxuLE8V0Xh/SZ9QuP3a7Yl4zTbKGC6/eMvz+wrs9M8uwsUZJEUk/NQBSj8P3MEpaPBJ46U+aCe3j5Ylq1bjV9nMOZCRiuf1C5uDkSNtzzigBlyJ/JYllZscVmxzoY2R9zSgZPpRLJMFOxs1AFdUZto3ngmgCDcu9sLkdeelPXbIpwqhu1VBKI3Ic9Kijm5d84x0oAtJdiGcsQNw6cUkuqSyNl2Yc9BxWfFOskuCMnNLeMDLhU5oAnvAu3Oc8dDWbI0CvjLVZuzJt6dqypVy+cUAblq0JhUDn0Bpux2kwo+btnpWbaP+9QOdqittriDCJE2XPegCvNt3qhHzd6qzKsJJccNwK2jZoqLJI4zWZdQ/aZAgPAOaAM95UztA+lFWlSBC46stFAGfQ3Q0UHocUAPtgP4hU8Y2g72B9KpRhgal25IHOTQBctAfMbc5wfetW1jRp/vZGKyraEtgMcV0On2cSJneCaAJ7eOGGTfnjuKs3cyiIsjALjpWbexFeEPJqG3SQkLLnB6UAadhHuh8wKTzmrkqs4G0ECksibdQjAbfUUy8utkm3IAPegCJVlKMhDYB7VHFYnzt6IQeuR1p4kljLM0ilD0xWvpqGVP9cn50ASafCpuY/O3Bvet2+0PTb+3KzznzKpRxRxJvZldvrUj3NuiB3baPXNAHM6h4GQOzwyhkHQCk0/RTCpj2Hf71vTXsOzfb3IweoNZN7rMW4EEl+mVoAzdU0xkO543wOwqxZ6PHcQBni2D1Na1ozzopKs6t3btWmMeQYsBce9AHLPYwROVUbqrLokdzOCV+XPNX9SguYncw4wOTWdZ3k7+YofGPWgDp4tH0y3t1Hyk45xWdJ4aSeUywwnb9Kh0672ZDZkf0NdPYanP5CpIgVf9kigDFhtPsikLb9Palji8xWCRgnOSDXQrcq/+sj69MCoLxQsTtHsTPNAGTJJLE21o0XjjFYWqXJ37nzj7uKuyXJguRJNIGT0qpqOpWtxMGRV2Ac0AYs1x84jyVJHWnRvKuMBmHc1R1SZbib92pGOmKuWEri3CvlQO5oAiuoRLKJGUovfJqD92SSAcDrWi0kc/yk7h6VSuZo0kWNIyFzg0AMS3RIxMemeBQ7xBizYOaSW6hWbbyYwKoXV0jHMajFAD7i83nA6dKqE5OTSZyM0UAJipoDnKrwfWoqlRlWNiPvUASveuP3bMTinW1z5cm85xVDkvuPU0+VyFAA60AJPITKzDjcaKk2qVBY0UAMooooAO9W4wuVzjJqp9KeEbehzxQBeuUchccU62lMD/ADy4+tVp5HiVWzuBponFwoBAB9TQBrpOZZA2/Kr1rXTLWzbADgdRWHBE0VufLAcGp7a9aDdsOW7qaAJ4dQeNTG2SM9TRPMCOSWz+lVJ74TOCIto78Uv2oCP93gNQBoWBikG2VyPrWlFYLAC6Sk+wNZFlbxzASXPLA8EcVuIkYhyMgUAR/wCkxvhWLKatW2yQMJCfo3SqjfuJg5LlPTNXrWeFskADPY0AZWsWs0eWttpU9hXPTzyo6q/yv15rp9TfIPlEh/SuY1CC6eTdtDNQB02hXd5LGYzIoHbmtO5069BaX7RuPZVPJrmdHOAFu2KehHFdEYLOONnS8kyw55oAfFp2qSASXEE8UD8K7oQp/GkuvDEwiLwuAxGT2r2HWtTtkuEsLjWLy9a8061tVsJBtt7cssf75WJIDAA87eNx59eli8PaLJaJKljlLWUwlGR0WX5CcklyWGRwy7QaAPmq206e1lAnfAB5J7V0lpCk4WOB/MkY7QijJJ9hXXxWGm6loKeIV0aF714Z1TTI3laGZo5I1Bxu3k4kY8N2Hvmt4UggtPiToQGlPpzS3Nuxt/MLhCXHTOSBkdCSR60AcxHcNA2HlTPGBmq1zeSSK+FQjOB6V6X4e0zw5ryrf3Fl9migmmiWFGaQz7Y1Zd65BZznohUHsBU8mh+HE1Ka7XTJjEtvHm2eCQbXZ3GVhEnmYwgyTIAMk4wwwAeH3sQlZI5D87nAUdz6UPpcEceJUaJh/C3B/Gva38M6XovjnT47DSm1N5dVjV2MpVrFRtZWUg4UZPR92QMDnmvFfFV6brxTrTPKxxf3CkEkn/WNQBmXr2qJshA3Dviqqu3lEzMCntU8jwxQtIELdsVBBCk7ea52x/3TQBBHIoJMRO7tUcxfeGlxitdILZfnjQnHtWbNeRzSshTp7UAZ0gO5iOh/Wq5BHUVo3ciIqrjFUpSCeKAIj0ooooAKMUE460Ag9CDQAYprtgAYzmnkEDkEUx+cetAEpjIj3/pRTBMcbe1FABQ3ANGaOtACRS4PIqWJvMbB4qLGDxTlODkcGgCVpGRiGjLIOlMkZXGVXaM0wknqant9rnZJ07UAW7WRoirBug6etWBItxJuCbWrOnaWEqQPkFIjOZBKpIHpQBbuZvLYjNR2bb3DBc89Kr3jyyncBin2YmgdT6+tAG3cH90jZKEelXtNuvO/dmTIFZFrLLcSAMAQDW0iW0bfOu1vagDoUjjkhwTkYrC1CyjaX5JZE9xVuyuvKfaOYj3p813FIHDRjGeDQBiTQz2u47y6HuetJDKq/Mx4PPNWHQySHYzeX6Hmh7KWXhGGPpQATS2l2oUg7h/dFNS3Vk2KH/4EcUwaReFh5TBG9a0IGe1jaO7YO4H3hQA62W+Eona5eVsBQHbJAAA/St+48Q6k8SrFfXIlxtyXOQB0FczaXztMI4yADxk1fmVoUy+CcZ4oAmhvLuyaGTz5laIs0bRyEFM9duOme9SR+IB9qEpnkS6B3eYXJbd2O7r+NYct05PzZIHNUvMjknz5eTQBqf2pLGiNa3Msckb702uRtOMZHv70xte1F7h7mW9uftMkflPL5rBmXuCc5wQBWZeXUbDCQAEdazmuJn+WOPH1oA1bzU7qISvHe3K+aF8zbKw37fulvp2rOS4eUkrtMjsWZ2OSSepPrTI4ZcF52yPQVVuJfLyIlI5oA6VbWGS0YTTqJD6VgTultcFDLvUdBVWW5lKrtBzUOx2O515oA2opnePAkCL61WuZYRIqxNufucVR84hdtIrjrxmgC5cp5gBqnNF83FWortUQhsE1TYS3Mp28YoAj6ZoqVbYmJg+felgtyxwfu0AQY8w45p6QiNs96usiWi54JNUpXZ3z0zQBJK+4AVXXIc8U4HijpQAUUUUAIIyRntS8DirNlt2lZBkU6a3V8mJsUAVOlInJpzRSLw3IpFGKAJ/k/u1FJjd8vFJsZjndTCrZPNAFmO9MamORd4PTPamvIcfISo9BUIU45peaAHCRhyzEirMd4cYZM+lVMZ61Ku9VyBwKANXSFZXZ9pGa3Bewv+5khOR/HWRo2qRJtWVMjPNdIZLOdCUAXNAFN/KC/umP0q5ZwruQucqR0qErHCcxlX9qs22JG3SKUHtQBpvEiwj7Oig+9ViHMbCQKrdiKmJjmj2QyjdVeOKePdvIPp3oAp3bXEMe8Hdisp5558+ZHgGtW7vGVCkifSqK3JdNpUAetAFOOPZJu3Y9qtXGohQEaXYOmaQRQMfmmG70qrc2LOdwjDp9aAI8SXEp8uUyL/eHAFMuRLbNww6c0xYJImxCSmar3kUwIJl3UAH2mJ+pII61It0qn92Nx96yw26Qq3BrWtLZVj3qOfrQAk0srJvVce1ZM7vuO78qu3jSliBWdh8nzOtADllK8tSmZj0PFQuMkA08qF5FACood+TipDEoBIPNNi2lvmFTIsZbBOOaAFt7R5RkDOKuR+XCm2QhWHpUtuqhSscoGeKmW1s4V8y4bew96AKLq9wwMAwv86f9kYDdNKI8dhTbvU1Q7LbCp7VnSyvJy7k0AS3UsZyind71WU5FIVBIpwGKADFFFIz7eMZNAC0VJbW8s8ihV4NFAEpiZHJHSoFkzJgk8Hmrw+61UYf9c31oAuXLFxuAwoGKq7QTkGrL/wDHs1V16UAREfNweKVSVHPNDfeNIegoAUnmkoooAO4qxBcMhClQVNVj95aev3xQBqQxRyAkgD6CrDZjjwhPNVrToKtXH+rWgBbSWbzQF5ret5ZfL2MM/WsfSf8AXiugh60AUmxbybl3rn0pxvnj5Ejn61buvuVlXfQ/SgCpqNw1yykSYx1rOM8kWFkbcKH/AIqrj71AE7XERYDDLnvmpRdTpHhJyU9M1Rv/ALgqK17fSgC48zuDuZlXvUZwE3RyMT3yOtTP92nv/qjQBmyuJGJHB6UwSSrwsr4qI/eP1p6/doAdvkJyZGNIST1OaSigBCMnNOPNJRQAEUhxS0GgBySbOadJK8yhR0qE9KdB3oAkSFY2BbnNNY5cnt2p0vQVHQAUUDrQKAFCljgVatrNZGHnPgCoIutTt0FAFqe8+ywlIlHpuoqlef6uigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoonographic image obtained during EUS showing invasion of an ampullary lesion into the pancreatic head (T3). The tumor clearly penetrates the muscularis propria.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of A James Moser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_58_34735=[""].join("\n");
var outline_f33_58_34735=null;
